WO2001094629A2 - Cancer gene determination and therapeutic screening using signature gene sets - Google Patents
Cancer gene determination and therapeutic screening using signature gene sets Download PDFInfo
- Publication number
- WO2001094629A2 WO2001094629A2 PCT/US2001/010838 US0110838W WO0194629A2 WO 2001094629 A2 WO2001094629 A2 WO 2001094629A2 US 0110838 W US0110838 W US 0110838W WO 0194629 A2 WO0194629 A2 WO 0194629A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- expression
- cancer
- genes
- agent
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to methods of assaying potential anti- tumor agents based on their modulation of the expression of specified sets of genes and methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the patterns of expression of such gene sets.
- Screening assays for novel drugs are based on the response of model cell based systems in vitro to treatment with specific compounds.
- Various measures of cellular response have been utilized, including the release of cytokines, alterations in cell surface markers, activation of specific enzymes, as well as alterations in ion flux and/or pH.
- Some such screens rely on specific genes, such as oncogenes (or gene mutations).
- characteristic sets of gene sequences whose expression, or non-expression, or change in expression, either an increase or decrease thereof, are indicative of the cancerous or non-cancerous status of a given cell. More particularly, such genes whose expression is changed in cancerous, as compared to non- cancerous cells, from a specific tissue (in particular, any of those disclosed herein) are genes that include one of the nucleotide sequences of SEQ ID NO: 1 - 8447, or sequences that are substantially identical to said sequences. Such a change in expression may be an increase or a decrease in expression or activity of the gene or gene sequences disclosed herein. It is another object of the present invention to provide methods of using such characteristic, or signature, gene sets as a basis for assaying the potential ability of selected chemical agents to modulate upward or downward the expression of said characteristic, or signature, gene sets.
- the present invention relates to a process for determining a cancer initiating, facilitating or suppressing gene comprising the steps of contacting a cancerous cell with a cancer modulating agent and determining a change in expression of a gene selected from the group consisting of the gene sequences of SEQ ID NO: 1 - 8447 and thereby identifying said gene as being a cancer initiating or facilitating gene.
- Said genes may, for example, be oncogenes, cancer facilitating or promoting genes, or cancer suppressor genes.
- Said agents may increase or decrease gene expression.
- the present invention also relates to a process for treating cancer comprising contacting a cancerous cell with an agent having activity against an expression product encoded by a gene sequence selected from the group consisting of SEQ ID NO: 1 - 8447, which process may be conducted either ex vivo or in vivo.
- agents may comprise an antibody or other molecule or portion that is specific for said expression product.
- the present invention further relates to process for determining a cancer initiating, facilitating or suppressing gene in a cancer cell comprising determining a change in expression of a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
- Such change in expression is especially a change to a difference in copy number and said difference, either an increase or decrease thereof, and wherein said change is monitored or otherwise determined as a change in messenger RNA formation.
- Such change can be readily used to diagnose a cancerous condition, either in vivo or ex vivo.
- the present invention still further relates to a process for treating cancer comprising inserting into a cancerous cell a gene construct comprising an anti-cancer gene operably linked to a promoter or enhancer element such that expression of said anti-cancer gene causes suppression of said cancer and wherein said promoter or enhancer element is a promoter or enhancer element modulating a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447, wherein said gene may be a cancer suppressor gene, or where said gene encodes a polypeptide having anticancer activity, such as one with apoptotic activity.
- the present invention relates to a process for determining functionally related genes comprising contacting one or more gene sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447 with an agent that modulates expression of more than one gene in such group and thereby determining a subset of genes of said group.
- Said functionally related genes include genes modulating the same metabolic pathway or encoding functionally related polypeptides or where said expression is modulated by the same transcription activator or enhancer sequence.
- the present invention also relates to a method for producing a product comprising identifying an agent according to the process of claim
- said product is the data collected with respect to said agent as a result of said process and wherein said data is sufficient to convey the chemical structure and/or properties of said agent.
- the present invention relates to methods of assaying potential antitumor agents based on their modulation of the expression of specified sets of genes and methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the patterns of expression of such gene sets and for determining cancer-inducing or regulating genes, and gene sets, based on common expression or regulation of such genes, or gene sets.
- model cellular systems using cell lines, primary cells, or tissue samples are maintained in growth medium and may be treated with compounds that may be at a single concentration or at a range of concentrations.
- cellular RNAs are isolated from the treated cells, primary cells or tumors, which RNAs are indicative of expression of selected genes.
- the cellular RNA is then divided and subjected to analysis that detects the presence and/or quantity of specific RNA transcripts, which transcripts may then be amplified for detection purposes using standard methodologies, such as, for example, reverse transcriptase polymerase chain reaction (RT-PCR), etc.
- RT-PCR reverse transcriptase polymerase chain reaction
- RNA transcripts are determined from these measurements and a metric derived for the type and degree of response of the sample to the treated compound compared to control samples.
- characteristic, or signature sets of genes and gene sequences whose expression is, or can be, as a result of the methods of the present invention, linked to, or used to characterize, the cancerous, or non-cancerous, status of the cells, or tissues, to be tested.
- the methods of the present invention identify novel anti-neoplastic agents based on their alteration of expression of small sets of characteristic, or indicator, or signature genes in specific model systems.
- the methods of the invention may therefore be used with a variety of cell lines or with primary samples from tumors maintained in vitro under suitable culture conditions for varying periods of time, or in situ in suitable animal models.
- certain genes have been identified that are expressed at levels in cancer cells that are different than the expression levels in non-cancer cells.
- the identified genes are expressed at higher levels in cancer cells than in normal cells.
- the identified genes are expressed at lower levels in cancer cells as compared to normal cells.
- the present invention relates to process for screening for an anti-neoplastic agent comprising the steps of:
- such change in expression may be an increase or a decrease in expression or activity. More particularly, the present invention relates to a process for screening for an anti-neoplastic agent comprising the steps of:
- step (b) exposing a known cancerous cell to a chemical agent to be tested for antineoplastic activity; (b) allowing said chemical agent to modulate the activity of one or more genes present in said cell wherein said genes include or comprise one of the sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447, sequences substantially identical to said sequences, or the complements of any of the foregoing; (c) determining the expression of one or more genes of step (b);
- said chemical agent to be tested modulates the expression of more than one said gene, especially where it modulates at least two said genes, more especially where at least 3, or at least 5 of said genes, or even 10 or more of said genes in said signature set, are modulated. In a preferred embodiment, all of said genes are modulated.
- said gene modulation is downward modulation, so that, as a result of exposure to the chemical agent to be tested, one or more genes of the cancerous cell will be expressed at a lower level (or not expressed at all) when exposed to the agent as compared to the expression when not exposed to the agent.
- a selected set of said genes are expressed in the reference cell but not expressed in the cell to be tested as a result of the exposure of the cell to be tested to the chemical agent.
- said chemical agent causes the gene, or genes, of the tested cell to be expressed at a lower level than the same genes of the reference, this is indicative of downward modulation and indicates that the chemical agent to be tested has anti-neoplastic activity.
- exposure of said cells to be tested to the chemical agent, especially one suspected of having anti-neoplastic activity may result in upward modulation of said genes of the cell to be tested.
- Such upward modulation is interpreted as meaning that said genes are expressed where previously not expressed, or else are expressed in greater quantities when exposed to the agent as compared to non-exposure to the agent.
- Such upward modulation may be taken as indicative of anti-neoplastic activity by the tested chemical agent(s) of the gene, or genes, so modulated results in lower neoplastic activity on the part of such cells, such as where increased expression of the gene, or genes, results in decreased growth and/or increased differentiation of said cells away from the cancerous state.
- genes useful in the assay processes include, respectively, as a part thereof at least one of the sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447, or sequences substantially identical thereto. Such sequences also include sequences complementary to any of the sequences disclosed herein.
- sequences at least 90% identical to a sequence selected from SEQ ID NO: 1 - 8447 preferably at least about 95% identical to such a sequence, more preferably at least about 98% identical to such sequence and most preferably 100% identical to such a sequence are specifically contemplated by all of the processes of the present invention.
- sequences encoding the same proteins as any of these sequences, regardless of the percent identity of such sequences are also specifically contemplated by any of the methods of the present invention that rely on any or all of said sequences, regardless of how they are otherwise described or limited.
- any such sequences are available for use in carrying out any of the methods disclosed according to the invention.
- Such sequences also include any open reading frames, as defined herein, present within any of the sequences of SEQ ID NO: 1 - 8447.
- percent identity when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence”).
- the Percent Identity is then determined according to the following formula:
- C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.
- portion when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence.
- residues such as amino acid residues
- fragment when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence.
- the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide.
- such terms refer to the products produced by treatment of said polynucleotides with any of the common endonucleases, or any stretch of polynucleotides that could be synthetically synthesized.
- DNA segment refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector.
- segments are provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes.
- Sequences of non- translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.
- the term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding in vivo for the native expression product of the gene.
- the coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.
- nucleotide sequence refers to a heteropolymer of deoxyribonucleotides.
- DNA segments encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.
- expression product means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).
- fragment when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.
- primer means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'-OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.
- promoter means a region of DNA involved in binding of RNA polymerase to initiate transcription.
- enhancer refers to a region of DNA that, when present and active, has the effect of increasing expression of a different DNA sequence that is being expressed, thereby increasing the amount of expression product formed from said different DNA sequence.
- ORF open reading frame
- reference to a DNA sequence includes both single stranded and double stranded DNA.
- specific sequence unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded
- relative antineoplastic activity may be ascertained by the extent to which a given chemical agent modulates the expression of genes present in a cancerous cell.
- a first chemical agent that modulates the expression of a gene associated with the cancerous state i.e., a gene that includes one of the sequences disclosed herein and present in cancerous cells
- a second chemical agent tested by the assays of the invention is thereby deemed to have higher, or more desirable, or more advantageous, anti-neoplastic activity than said second chemical agent.
- first and second chemical agents modulate expression of more than one of said genes, but where the second modulates expression of, for example, five said genes, whereas the first modulates expression of only three of said genes, especially where the three form a subset of the five, then the second chemical agent is deemed a more potent anti-neoplastic agent than the first.
- anti-neoplastic activity as determined using the assays of the present invention, may necessarily include combinations of the foregoing possibilities, which are in no way to be considered limiting.
- the genes whose activity is to be determined with and without the presence of the compound to be evaluated for antitumor activity may be any one, or several, or any combination of the gene sequences disclosed herein as SEQ ID NO: 1 - 8447.
- how the gene sequences are employed in such assays depends on the pattern of gene expression disclosed for the signature sets for the different organs and tissues. For example, a sequence that is expressed in cancerous cells but not in normal cells will identify a a potential anticancer agent by that agent's ability to decrease expression of the sequence, or sequences, in tumor cells.
- sequences, or sequences, expressed in normal but not tumor cells will identify a potential antitumor agent by its ability to increase expression in the tumor cells.
- sequences are expressed in both cancer and normal cells but are expressed at a higher level in one than in the other, and vice versa.
- sequences, or signature gene sets are utilized to determine the cancerous state of a cell or use of an agent to treat a cancerous condition.
- the present invention relates to a process for screening for an anti-neoplastic agent comprising the steps of (a) exposing cells to a chemical agent to be tested for antineoplastic activity, and (b) determining a change in expression of at least one gene of a signature gene set, or a sequence that is at least 95% identical thereto, wherein a change in expression is indicative of anti-neoplastic activity.
- a change in expression is intended to mean a change include any activity of the gene, and may be an increase or decrease thereof.
- such change in activity may be a change in expression or other activity of at least 1 such gene, such as 5 or 10, or more of the genes of a signature set, even as many as half of such genes or even of all of the genes of a particular gene set.
- the gene expression to be measured is commonly assayed using RNA expression as an indicator.
- RNA expression as an indicator.
- gene expression either absolute or relative, such as where the expression of several different genes are being quantitatively evaluated and compared, for example, where chemical agents modulate the expression of more than one gene, such as a set of 3, 4, 5, or more genes, is determined by the relative expression of the RNAs encoded by such genes.
- RNA may be isolated from samples in a variety of ways, including lysis and denaturation with a phenolic solution containing a chaotropic agent (e.g., triazol) followed by isopropanol precipitation, ethanol wash, and resuspension in aqueous solution; or lysis and denaturation followed by isolation on solid support, such as a Qiagen resin and reconstitution in aqueous solution; or lysis and denaturation in non-phenolic, aqueous solutions followed by enzymatic conversion of RNA to DNA template copies.
- a chaotropic agent e.g., triazol
- steady state RNA expression levels for the genes, and sets of genes, disclosed herein will have been obtained. It is the steady state level of such expression that is affected by potential anti-neoplastic agents as determined herein. Such steady state levels of expression are easily determined by any methods that are sensitive, specific and accurate.
- Such methods include, but are in no way limited to, real time quantitative polymerase chain reaction (PCR), for example, using a Perkin-Elmer 7700 sequence detection system with gene specific primer probe combinations as designed using any of several commercially available software packages, such as Primer Express software.
- PCR polymerase chain reaction
- solid support based hybridization array technology using appropriate internal controls for quantitation, including filter, bead, or microchip based arrays, solid support based hybridization arrays using, for example, chemiluminescent, fluorescent, or electrochemical reaction based detection systems.
- a set of genes useful in evaluating, or screening, or otherwise assaying, one or more chemical agents for anti-neoplastic activity in the assays disclosed herein will have already been shown to have differences in the ratios of steady state RNA levels in cancer cells , or tissues, relative to normal, or non-tumorous cells or tissues, or will have exhibited differences in the expression ratios in tumor samples compared to normal samples between genes in a given subset of the set of genes disclosed herein, or will have gene expression that has increased from undetectable levels to detectable levels, or vice versa, as the case may be, especially where sensitive detection methods are employed, or conversely will have decreased from detectable levels to undetectable levels with such procedures, especially sensitive procedures.
- genes, and gene sequences, useful in practicing the methods of the present invention are genes that are found to be selectively expressed in, or not expressed in, cancer cells as compared to non-cancer cells, or in which expression is down-regulated or up-regulated, as the case may be, in cancerous cells as compared to non-cancerous cells.
- these may include genes, or sets of genes, expressed in cancer cells but absent from, or inactive in, non-cancerous cells, or may include genes, or sets of genes, expressed in non-cancerous cells, but not expressed in cancer cells.
- the genes useful in practicing the present invention may be more expressed, or less expressed, in a cancerous cell relative to a non- cancerous cell.
- Such genes are generally those comprising the sequences of SEQ ID NO: 1 - 8447.
- the present invention further relates to a process for determining the cancerous status of a test cell, comprising determining expression in said test cell of at least one gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NO: 1 - 8447, or a nucleotide sequence that is at least 95% identical thereto, and then comparing said expression to expression of said at least one gene in at least one cell known to be non-cancerous whereby a difference in said expression indicates that said cell is cancerous.
- the present invention is directed to a process for determining the cancerous status of a cell to be tested, comprising determining the presence in said cell of at least one gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NO: 1 - 8447, including sequences having substantial identity homologous to said sequences, or characteristic fragments thereof, or the complements of any of the foregoing and then comparing the pattern of said gene presence and/or absence with that found for a cell known, or believed, to be non-cancerous, or normal, at least with respect to its genetic complement.
- genes that include at least one of the sequences of SEQ ID NO: 1 - 8447 up regulation of expression in cancer cells (as compared to non-cancer cells, which may lack said genes, or said gene expression, altogether) is indicative of a cancerous, or potentially cancerous, condition.
- the present invention relates to embodiments wherein the genetic pattern is the modulation of expression of more than one gene, preferably 3, 4, or 5 genes, and even includes patterns where there is a modulation of expression of as many as 10, or more, genes.
- a genetic pattern is the modulation of expression of 5 genes in a cancerous cell as compared to a non-cancerous cell from the same tissue type, such as a cancerous colon cell or other cancerous tissue cell, such as any of the organs or tissues described herein as related to specifically recited SEQ ID NOs.
- a non-cancerous cell of the same tissue or organ such a pattern indicates a likelihood that such genes (i.e., the modulation of expression of those 5 genes) is an indicator of cancerous status and thereby provides a means of diagnosing a cancerous, or potentially cancerous, status.
- colon especially colon adenocarcinoma
- SEQ ID NO: 334-522 would represent a signature set or signature gene set for colon. The same is true for each of the organs and tissues listed below with their respective signature sets or signature gene sets.
- SEQ ID NO: 1068-2459 for breast, wherein SEQ ID NO: 1068-1255 represent genes expressed in infiltrating ductal carcinoma of the breast that are not expressed at detectable levels in normal breast, wherein SEQ ID NO: 1256-1459 represent genes expressed in breast carcinoma that are not expressed at detectable levels in normal breast, wherein SEQ ID NO: 1459-1664 represent genes expressed in infiltrating lobular carcinoma of the breast that are not expressed at detectable levels in normal breast, wherein SEQ ID NO: 1665-2067 represent genes expressed in normal breast that are absent or not expressed in infiltrating ductal carcinoma of the breast, and wherein SEQ ID NO: 2068-2459 represent genes expressed in normal breast cells but absent or not expressed in infiltrating lobular carcinoma of the breast that are not expressed at detectable levels in normal breast.
- SEQ ID NO: 2460-2773 represent genes or gene sequences expressed in stomach cancer that are not expressed at detectable levels in normal stomach cells, and wherein SEQ ID NO: 2774-3027 represent genes or gene sequences expressed in normal stomach cells cancer that are not expressed at detectable levels in stomach cancer cells.
- SEQ ID NO: 3028-5303 for lung, wherein SEQ ID NO: 3028-3119 represent genes or gene sequences expressed in lung adenocarcinoma that are not expressed at appreciable levels in normal lung cells, wherein SEQ ID NO: 3120-3322 represent genes or gene sequences expressed in normal lung cells that are not expressed at appreciable levels in lung adenocarcinoma, wherein SEQ ID NO: 3323-3570 represent genes or gene sequences expressed in non-cancerous lung tissue that are not expressed at appreciable levels in malignant lung samples, wherein SEQ ID NO: 3571-3777 represent genes or gene sequences expressed in malignant lung samples that are not expressed at appreciable levels in non-malignant lung cells, wherein SEQ ID NO: 3778-3836 represent genes or gene sequences expressed in both normal and malignant lung adenocarcinoma but are up-regulated by at least about 2 fold in lung adenocarcinoma, wherein SEQ ID NO: 3837-3980 represent genes or gene sequences
- SEQ ID NO: 5304-5886 for thyroid, wherein SEQ ID NO: 5304-5408 represent genes or gene sequences expressed in thyroid papillary carcinoma that are not found in normal thyroid tissue, wherein SEQ ID NO: 5409-5602 represent genes or gene sequences expressed in normal thyroid cells that are not expressed in thyroid papillary carcinoma and wherein SEQ ID NO: 5603-5886 represent genes or gene sequences expressed at a level at least about a 5 fold higher level in thyroid papillary carcinoma relative to normal thyroid cells.
- SEQ ID NO: 5887-6147 for esophagus, wherein SEQ ID NO: 5887-6015 represent genes or gene sequences expressed in esophagus adenocarcinoma but not in normal esophagus from the same patients and wherein SEQ ID NO: 6016-6147 represent genes or gene sequences expressed in normal esophagus but not in esophagus adenocarcinoma samples from the same patients.
- SEQ ID NO: 6148-6472 for ovary, wherein SEQ ID NO: 6148-6371 represent genes or gene sequences expressed only in malignant ovarian carcinomas, wherein SEQ ID NO: 6372-6424 represent genes or gene sequences expressed only in normal ovarian tissues and wherein SEQ ID NO: 6425-6472 represent genes or gene sequences expressed only in metastatic ovarian cancer.
- SEQ ID NO: 6473-7473 for kidney This further includes SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney, wherein SEQ ID NO: 6473-7473 for kidney,
- ID NO:6473-6615 represent genes or gene sequences expressed in normal kidney but not in clear cell carcinoma of the kidney
- SEQ ID NO: 6616-6685 represent genes or gene sequences expressed in clear cell carcinoma cells but not in normal kidney cells
- SEQ ID NO: 6686- 6973 represent genes or gene sequences expressed in normal kidney cells but not in renal cell carcinoma of the kidney
- SEQ ID NO: 6974-7156 represent genes or gene sequences expressed in renal cell carcinoma but not in normal kidney
- SEQ ID NO: 7157-7229 represent genes or gene sequences expressed in normal kidney but not in Wilm's tumor cells
- SEQ ID NO: 7230-7473 represent genes or gene sequences expressed in Wilm's tumor but not in normal kidney cells.
- SEQ ID NO: 7474-8131 for prostate, wherein SEQ ID NO: 7475-7833 represent genes or gene sequences expressed in prostate adenocarcinoma but not appreciably expressed in normal prostate cells, wherein SEQ ID NO: 7834-8071 represent genes or gene sequences expressed in normal prostate cells but not expressed at appreciable levels in prostate adenocarcinoma and wherein SEQ ID NO: 8072-8131 represent genes or gene sequences for ribosomal proteins that are highly expressed in prostate adenocarcinoma but are not expressed at appreciable levels in normal prostate cells.
- SEQ ID NO: 8132-8447 for pancreas, wherein SEQ ID NO: 8132-8358 represent genes or gene sequences expressed in normal pancreas but not in pancreas adenocarcinoma and wherein SEQ ID NO: 8359-8447 represent genes or gene sequences expressed in pancreas adenocarcinoma but not in normal pancreas.
- the gene patterns indicative of a cancerous state need not be characteristic of every cell found to be cancerous.
- the methods disclosed herein are useful for detecting the presence of a cancerous condition within a tissue where less than all cells exhibit the complete pattern.
- a set of selected genes comprising sequences homologous under stringent conditions, or at least 90%, preferably 95%, identical to at least one of the sequences of SEQ ID NO: 1 - 8447, and wherein the signature set is comprised of genes expressed and/or up-regulated in cancer cells relative to normal cells, as disclosed above for the signature gene sets used for practicing the invention, may be found, using appropriate probes, either DNA or RNA, to be present in as little as 60% of cells derived from a sample of tumorous, or malignant, tissue while being absent from as much as 60% of cells derived from corresponding non-cancerous, or otherwise normal, tissue (and thus being present in as much as 40% of such normal tissue cells).
- such gene pattern is found to be present in at least 70% of cells drawn from a cancerous tissue and absent from at least 70% of a corresponding normal, non-cancerous, tissue sample. In an especially preferred embodiment, such gene pattern is found to be present in at least 80% of cells drawn from a cancerous tissue and absent from at least 80% of a corresponding normal, non-cancerous, tissue sample. In a most preferred embodiment, such gene pattern is found to be present in at least 90% of cells drawn from a cancerous tissue and absent from at least 90% of a corresponding normal, non-cancerous, tissue sample. In an additional embodiment, such gene pattern is found to be present in at least 100% of cells drawn from a cancerous tissue and absent from at least 100% of a corresponding normal, non-cancerous, tissue sample, although the latter embodiment may represent a rare occurrence.
- the presence or absence of expression of one or more selected gene sequences may be indicative of a cancerous status for a given ceil, the mere presence or absence of such a gene pattern may not alone be sufficient to achieve a malignant condition and thus the level of expression of such gene pattern may also be a significant factor in determining the attainment of a cancerous state.
- a pattern of genes may be present in both cancerous and non-cancerous cells, the level of expression, and determined by any of the methods disclosed herein, all of which are well known in the art, may differ between the cancerous versus the non-cancerous cells.
- it becomes essential to also determine the level of expression of one or more of said genes as a separate means of diagnosing the presence of a cancerous status for a given cell, groups of cells, or tissues, either in culture or in situ.
- a determination of an anticancer agent using the signature gene sets for the various organs and tissues described above is based on patterns of modulation of such genes so that increase or decrease in expression of a gene due to the presence of such a potential agent may or may not be meaningful.
- the more genes in a gene set that are affected by said agent the more likely said agent is an effective therapeutic agent.
- agents may have different abilities to affect the genes of a signature gene set.
- a potential therapeutic agent say, agent A
- agent B causes a gene or group of genes of a characteristic or signature gene set, or even all of the genes of said gene set, to exhibit decreased expression, such as where a lower amount of mRNA is expressed from said gene(s), or less protein is produced from said mRNA
- a second potential agent say, agent B
- agent B while modulating the activity of the same or related genes causes said expression to be reduced to half, such as where only half as much mRNA is transcribed or only half as much protein is translated from said mRNA as for agent A
- agent B is considered to have twice as much therapeutic potential as agent A.
- Such modulation or change of activity as determined using the assays disclosed herein may include either an increase or a decrease in activity of said genes or gene sequences.
- an agent that down-regulates said gene or genes, or gene sequences, or prevents their expression entirely is considered a potential antitumor agent within the present disclosure.
- an agent causes expression of a gene or genes, or gene sequences, expressed in normal cells but not in cancer cells, or where said agent up-regulates a gene or genes, or gene sequences, that are expressed in normal cells but not in cancer cells, or are up-regulated in normal cells but not in cancer cells, of the same organ or tissue type, said agent is considered to be a potential antitumor agent within the present disclosure.
- the present invention also relates to a method for producing a product comprising identifying an agent according to one of the disclosed processes for identifying such an agent wherein said product is the data collected with respect to said agent as a result of said identification process and wherein said data is sufficient to convey the chemical character and/or structure and/or properties of said agent.
- the present invention further relates to a process for determining the cancerous status of a cell to be tested, comprising determining the level of expression in said cell of at least one gene that includes one of the nucleotide sequences selected from the sequences of SEQ ID NO: 1 - 8447, including sequences substantially identical to said sequences, or characteristic fragments thereof, or the complements of any of the foregoing and then comparing said expression to that of a cell known to be non-cancerous whereby the difference in said expression indicates that said cell to be tested is cancerous.
- said expression is determined for more than one of said genes, such as 2, 3, 4, 5, or more such genes, considered as a set, and even as many as a set of 10 such genes.
- a set of genes, for example, 5 such genes may be found to be expressed at certain levels in cancer cells but are found to be expressed at lower levels (or not expressed at all) in non-cancerous, or normal, cells.
- a set of, for example, 5 such genes may be found to be expressed in normal (i.e., non- cancerous) cells but expressed at lower levels (or not expressed at all) in cancer cells.
- genes expressed in cancer cells but expressed at lower levels (or not at all) in non-cancer are selected from those that include one of the sequences, or fragments of sequences, including complementary sequences, selected from SEQ ID NO: 1 - 8447.
- the processes of the present invention include embodiments wherein said expression is the expression of more than one said gene, possibly at least three said genes, preferably at least 5 said genes, or even as many as 10 or more said genes.
- the process of the invention relates to situations wherein expression of said genes is higher in said cells to be tested than in said non-cancerous cells, or wherein expression of said genes is lower in said cells to be tested than in said non-cancerous cells.
- the cancerous, or non-cancerous, status of a cell, or tissue sample may be readily ascertained.
- colon or other cancers can be readily detected using the methods of the present invention.
- nucleotide sequence disclosed with respect to a specific sequence ID number is only a portion of the nucleotide sequence that encodes expression of the gene.
- expression of the gene may be determined by use of a nucleotide probe that hybridizes to messenger RNA (mRNA) transcribed from a portion of the gene other than the specific nucleotide sequence disclosed with reference to a sequence ID number as recited herein.
- mRNA messenger RNA
- the present invention further relates to a process for determining a cancer initiating, facilitating or suppressing gene comprising the steps of contacting a cell with a cancer modulating agent and determining a change in expression of a gene selected from the group consisting of the gene sequences of SEQ ID NO: 1 - 8447 and thereby identifying said gene as being a cancer initiating or facilitating gene.
- genes within the signature gene sets disclosed herein as SEQ ID NO: 1 - 8447 are found to play a direct role in the initiation or progression of cancer or even other diseases and disease processes. Because changes in expression of these genes (either up-regulation or down- regulation) are linked to the disease state (i.e. cancer), the change in expression may contribute to the initiation or progression of the disease. For example, if a gene that is up-regulated is an oncogene, or if a gene that is down-regulated is a tumor suppressors, such a gene provides for a means of screening for small molecule therapeutics beyond screens based upon expression output alone.
- genes that display up-regulation in cancer and whose elevated expression contributes to initiation or progression of disease represent targets in screens for small molecules that inhibit or block their function. Examples include, but are not be limited to, kinase inhibition, cellular proliferation, substrate analogs that block the active site of protein targets, etc. Similarly, genes that display down-regulation in cancer and whose absence results in initiation or progression of disease are valuable therapeutics for gene therapy.
- genes there are a variety of different contexts in which genes have been evaluated as being involved in the cancerous process.
- some genes may be oncogenes and encode proteins that are directly involved in the cancerous process and thereby promote the occurrence of cancer in an animal.
- other genes may serve to suppress the cancerous state in a given cell or cell type and thereby work against a cancerous condition forming in an animal.
- Other genes may simply be involved either directly or indirectly in the cancerous process or condition and may serve in an ancillary capacity with respect to the cancerous state. All such types of genes are deemed with those to be determined in accordance with the invention as disclosed herein.
- the gene determined by said process of the invention may be an oncogene, or the gene determined by said process may be a cancer facilitating gene, the latter including a gene that directly or indirectly affects the cancerous process, either in the promotion of a cancerous condition or in facilitating the progress of cancerous growth or otherwise modulating the growth of cancer cells, either in vivo or ex vivo.
- the gene determined by said process may be a cancer suppressor gene, which gene works either directly or indirectly to suppress the initiation or progress of a cancerous condition.
- Such genes may work indirectly where their expression alters the activity of some other gene or gene expression product that is itself directly involved in initiating or facilitating the progress of a cancerous condition.
- a gene that encodes a polypeptide, either wild or mutant in type, which polypeptide acts to suppress of tumor suppressor gene, or its expression product will thereby act indirectly to promote tumor growth.
- the process of the present invention includes cancer modulating agents that are themselves either polypeptides, or small chemical entities, that affect the cancerous process, including initiation, suppression or facilitation of tumor growth, either in vivo or ex vivo.
- Said cancer modulating agent may have the effect of increasing gene expression or said cancer modulating agent may have the effect of decreasing gene expression as such terms have been described herein.
- the present invention also relates to a process for treating cancer comprising contacting a cancerous cell with an agent having activity against an expression product encoded by a gene sequence selected from the group consisting of SEQ ID NO: 1 - 8447.
- genes within these signature gene sets represent individual targets for therapeutic intervention, based at least in part on their pattern(s) of expression.
- genes within the signature gene sets that encode cell surface molecules and are up-regulated in cancer as compared to normal cells.
- the proteins encoded by such genes due to their elevated expression in cancer cells, represent highly useful therapeutic targets for "targeted therapies" utilizing such affinity structures as, for example, antibodies coupled to some cytotoxic agent.
- an antibody or equivalent molecule that can specifically recognize the cell surface molecule (which could include an artificial peptide, a surrogate ligand, and the like) that is coupled to some agent that can induce cell death or a block in cell cycling offers therapeutic promise against these proteins.
- cell surface molecule which could include an artificial peptide, a surrogate ligand, and the like
- agent that can induce cell death or a block in cell cycling offers therapeutic promise against these proteins.
- suicide "bullets” against intracellular proteins include the use of so-called suicide "bullets" against intracellular proteins
- the process of the present invention includes embodiments of the above-recited process wherein said cancer cell is contacted in vivo as well as ex vivo, preferably wherein said agent comprises a portion, or is part of an overall molecular structure, having affinity for said expression product.
- said portion having affinity for said expression product is an antibody, especially where said expression product is a polypeptide or oligopeptide or comprises an oligopeptide portion, or comprises a polypeptide.
- Such an agent can therefore be a single molecular structure, comprising both affinity portion and anti-cancer activity portions, wherein said portions are derived from separate molecules, or molecular structures, possessing such activity when separated and wherein such agent has been formed by combining said portions into one larger molecular structure, such as where said portions are combined into the form of an adduct.
- Said anti- cancer and affinity portions may be joined covalently, such as in the form of a single polypeptide, or polypeptide-like, structure or may be joined non- covalently, such as by hydrophobic or electrostatic interactions, such structures having been formed by means well known in the chemical arts.
- the anti-cancer and affinity portions may be formed from separate domains of a single molecule that exhibits, as part of the same chemical structure, more than one activity wherein one of the activities is against cancer cells, or tumor formation or growth, and the other activity is affinity for an expression product produced by expression of genes related to the cancerous process or condition.
- a chemical agent such as a protein or other polypeptide
- an agent such as an antibody
- an agent having affinity for an expression product of a cancerous cell, such as a polypeptide or protein encoded by a gene related to the cancerous process, especially a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
- said expression product is a cell surface receptor, such as a protein or glycoprotein or lipoprotein, present on the surface of a cancer cell, such as where it is part of the plasma membrane of said cancer cell, and acts as a therapeutic target for the affinity portion of said anticancer agent and where, after binding of the affinity portion of such agent to the expression product, the anti-cancer portion of said agent acts against said expression product so as to neutralize its effects in initiating, facilitating or promoting tumor formation and/or growth.
- a cell surface receptor such as a protein or glycoprotein or lipoprotein
- binding of the agent to said expression product may, without more, have the effect of deterring cancer promotion, facilitation or growth, especially where the presence of said expression product is related, either intimately or only in an ancillary manner, to the development and growth of a tumor.
- binding of said agent to said expression product will have the effect of negating said tumor promoting activity.
- said agent is an apoptosis- inducing agent that induces cell suicide, thereby killing the cancer cell and halting tumor growth.
- the present invention further relates to a process for determining a cancer initiating, facilitating or suppressing gene in a cancer cell comprising determining a change in expression of a gene sequence, especially where said sequence is one selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
- the processes of the present invention take advantage of the correlation of changes in mRNA expression profiles of these signature gene sets with potential (depending on the form of cancer) changes in DNA copy number of the chromosomal regions wherein these genes are located.
- the precise nature of the change in mRNA expression e.g. a signature set of genes that are up-regulated at the transcriptional level
- All cancers contain chromosomal rearrangements, which typically represent translocations, amplifications, or deletions of specific regions of genomic DNA.
- a recurrent chromosomal rearrangement that is associated with a specific stage and type of cancer always affects a gene (or possibly genes) that play a direct and critical role in the initiation or progression of the disease.
- Many of the known oncogenes or tumor suppressor genes that play direct roles in cancer have either been initially identified based upon their positional cloning from a recurrent chromosomal rearrangement or have been demonstrated to fall within a rearrangement subsequent to their cloning by other methods. In all cases, such genes display amplification at both the level of DNA copy number and at the level of transcriptional expression at the mRNA level.
- At least some of the genes that are contained within signature gene sets disclosed herein display changes in their mRNA expression profiles (depending on the precise reading frame involved) within cancer samples due, in part, to changes in their DNA copy number as a result of specific chromosomal rearrangements in those cancer cells.
- the utilities that follow from this are (i) that the genes contained within these signature gene sets offer a time saving shortcut to the identification of novel chromosomal rearrangements, amplifications, or deletions that are associated with cancer, and/or (ii) represent key genes affected by such chromosomal rearrangements, amplifications, or deletions and, therefore, play a key role in the initiation or progression of the disease.
- Genes within the signature sets that identify changes in the DNA copy number thus afford an entry point into other forms of diagnostic assay for the initiation, staging, or progression of cancer to be conducted in tissue samples at the DNA level (e.g. if gene X identifies a novel chromosomal amplification associated with ⁇ cancer, then that specific chromosomal region defined by gene X would serve as the basis for a diagnostic assay for cancer, where genomic DNA is extracted from tissue samples and evaluated for the presence of the specific amplification), and also the rapid positional cloning of genes that play vital and direct roles in the initiation or progression of cancer.
- said change in expression may be determined by determining a change in gene copy number, wherein said change in copy number is an increase in copy number or wherein said change in copy number is a decrease in copy number.
- Such change in gene copy number may be determined by determining a change in expression of messenger RNA encoded by a particular gene sequence, especially where said sequence is one selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
- said gene may be a cancer initiating gene, a cancer facilitating gene, or a cancer suppressing gene.
- a cancer facilitating gene is a gene that, while not directly initiating or suppressing tumor formation or growth, said gene acts, such as through the actions of its expression product, to direct, enhance, or otherwise facilitate the progress of the cancerous condition, including where such gene acts against genes, or gene expression products, that would otherwise have the effect of decreasing tumor formation and/or growth.
- the present invention also provides a process for diagnosing a cancerous cell comprising determining a cancer initiating, facilitating or suppressing gene according to the above-described methods.
- the present invention also relates to a process for treating cancer comprising inserting into a cancerous cell a gene construct comprising an anti-cancer gene operably linked to a promoter or enhancer element such that expression of said anti-cancer gene causes suppression of said cancer and wherein said promoter or enhancer element is a promoter or enhancer element modulating a gene sequence selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447.
- each signature set is a collection of genes that share a gross common pattern of transcriptional regulation in cancer vs. normal (e.g. a signature set of genes that are transcriptionally up-regulated in cancer).
- analyzing and comparing the DNA sequences of the promoter regions of all the genes contained within the signature set serves to identify conserved stretches or motifs of sequences within subsets of genes that represent cis-acting elements that specifically drive a form of gene expression (e.g. increased transcriptional expression in cancer).
- the identification of such cis-acting regulatory elements is then available for use in driving the cancer-specific expression of suicide genes or toxins via genetic therapy using technology already well known in the art.
- said anti-cancer gene is a cancer suppressor gene or encodes a polypeptide having anticancer activity, especially where said polypeptide has apoptotic activity.
- the present invention such insertion of said gene construct into a cancerous cell is accomplished in vivo, for example using a viral or plasmid vector.
- a viral or plasmid vector Such methods can also be applied to in vitro uses.
- the methods of the present invention are readily applicable to different forms of gene therapy, either where cells are genetically modified ex vivo and then administered to a host or where the gene modification is conducted in vivo using any of a number of suitable methods involving vectors especially suitable to such therapies, such as the use of special viral vectors, including adeno-associated viruses and adenoviruses, as well as retroviruses and specially constructed plasmids to accomplish such therapies.
- special viral vectors including adeno-associated viruses and adenoviruses, as well as retroviruses and specially constructed plasmids to accomplish such therapies.
- retroviruses and specially constructed plasmids to accomplish such therapies.
- the present method also relates to a process for determining functionally related genes comprising contacting one or more gene sequences selected from the group consisting of the sequences of SEQ ID NO: 1 - 8447 with an agent that modulates expression of more than one gene in such group and thereby determining a subset of genes of said group.
- said functionally related genes are genes modulating the same metabolic pathway or said genes are genes encoding functionally related polypeptides.
- said genes are genes whose expression is modulated by the same transcriptional activator or enhancer sequence, especially where said transcriptional activator or enhancer increases, or otherwise modulates, the activity of a gene sequence selected from the group consisting of SEQ ID NO: 1 - 8447.
- the signature gene set disclosed herein also find use as the basis for small molecule assays for therapeutics based upon changes in expression profile.
- small molecule screens serve to identify changes in expression of genes within a signature set and thereby provide a tool for the identification of specific functional pathways and a means of assigning defined functions to novel genes.
- monitoring the transcriptional expression of the genes contained within the signature sets disclosed herein forms the basis of an assay for small molecule therapeutics.
- such screens facilitate the identification of small molecules that down-regulate the expression of the genes of the signature set within cancer cells. While such therapeutics make a cancer cell "look" more normal, based upon the expression of the genes within the signature set, what actually happens when such screens are put into practice is that all genes within the signature sets do not respond identically to each small molecule within a chemical compound library.
- an average signature set contains 200 different genes, for example, and the expression of all 200 genes is monitored in response to a library of some 50,000 chemical compounds, and subsets of genes within the signature set consistently change their patterns of expression in response to particular chemicals (e.g., 10 of the genes always change expression in a coordinated way, such as down-regulation of one gene within the group of 10) then it always causes the down-regulation of the other 9 specific genes as well.
- Such subsets or subgroups of genes within each signature set that change their expression in a coordinated way in response to chemical compounds represent genes that are located within a common metabolic, signaling, physiological, or functional pathway so that by analyzing and identifying such subsets one can (a) assign known genes and novel genes to specific pathways and (b) identify specific functions and functional roles for novel genes that are grouped into pathways with genes for which their functions are already characterized or described. For example, one might identify a subgroup of 10 genes within a signature set (5 known genes & 5 novel genes) that change expression in a coordinated fashion and for which the 5 known genes are involved in apoptosis thereby implicating the other 5 novel genes as playing a role in apoptotic cellular processes.
- the processes disclosed according to the present invention at once provide a novel means of assigning function to genes, i.e. a novel method of functional genomics, and a means for identifying chemical compounds that have potential therapeutic effects on specific cellular pathways.
- Such chemical compounds may have therapeutic relevance to a variety of diseases outside of cancer as well, in cases where such diseases are known or are demonstrated to involve the specific cellular pathway that is affected.
- any reference to particular buffers, media, reagents, cells, culture conditions and the like are not intended to be limiting, but are to be read so as to include all related materials that one of ordinary skill in the art would recognize as being of interest or value in the particular context in which that discussion is presented. For example, it is often possible to substitute one buffer system or culture medium for another and still achieve similar, if not identical, results. Those of skill in the art will have sufficient knowledge of such systems and methodologies so as to be able, without undue experimentation, to make substitutions that will optimally serve their purposes in using the methods and procedures disclosed herein.
- SW480 cells are grown to a density of 10 5 cells/cm 2 in Leibovitz's L-15 medium supplemented with 2 mM L-glutamine (90%) and 10% fetal bovine serum.
- the cells are collected after treatment with 0.25% trypsin, 0.02% EDTA at 37°C for 2 to 5 minutes.
- the trypsinized cells are then diluted with 30 ml growth medium and plated at a density of 50,000 cells per well in a 96 well plate (200 ⁇ l/well). The following day, cells are treated with either compound buffer alone, or compound buffer containing a chemical agent to be tested, for 24 hours.
- RNA is quantitated and 10 ng of sample in 1 ⁇ l are added to 24 ⁇ l of Taqman reaction mix containing 1X PCR buffer, RNAsin, reverse transcriptase, nucleoside triphosphates, amplitaq gold, tween 20, glycerol, bovine serum albumin (BSA) and specific PCR primers and probes for a reference gene (18S RNA) and a test gene (Gene X). Reverse transcription is then carried out at 48°C for 30 minutes.
- the sample is then applied to a Perlin Elmer 7700 sequence detector and heat denatured for 10 minutes at 95°C.
- Amplification is performed through 40 cycles using 15 seconds annealing at 60°C followed by a 60 second extension at 72°C and 30 second denaturation at 95°C.
- Data files are then captured and the data analyzed with the appropriate baseline windows and thresholds.
- the quantitative difference between the target and reference genes is then calculated and a relative expression value determined for all of the samples used. This procedure is then repeated for each of the target genes in a given signature, or characteristic, set and the relative expression ratios for each pair of genes is determined (i.e., a ratio of expression is determined for each target gene versus each of the other genes for which expression is measured, where each gene's absolute expression is determined relative to the reference gene for each compound, or chemical agent, to be screened).
- the samples are then scored and ranked according to the degree of alteration of the expression profile in the treated samples relative to the control.
- the overall expression of the set of genes relative to the controls, as modulated by one chemical agent relative to another, is also ascertained. Chemical agents having the most effect on a given gene, or set of genes, are considered the most anti-neoplastic.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001264559A AU2001264559A1 (en) | 2000-06-05 | 2001-05-30 | Cancer gene determination and therapeutic screening using signature gene sets |
EP01938990A EP1358349A2 (en) | 2000-06-05 | 2001-05-30 | Cancer gene determination and therapeutic screening using signature gene sets |
JP2002502169A JP2004509612A (en) | 2000-06-05 | 2001-05-30 | Oncogene determination and therapeutic screening using characteristic genes |
CA002411601A CA2411601A1 (en) | 2000-06-05 | 2001-05-30 | Cancer gene determination and therapeutic screening using signature gene sets |
US10/843,641 US20050064454A1 (en) | 2000-06-05 | 2004-05-11 | Cancer gene determination and therapeutic screening using signature gene sets |
Applications Claiming Priority (84)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20947300P | 2000-06-05 | 2000-06-05 | |
US20953100P | 2000-06-05 | 2000-06-05 | |
US60/209,473 | 2000-06-05 | ||
US60/209,531 | 2000-06-05 | ||
US23313300P | 2000-09-18 | 2000-09-18 | |
US23361700P | 2000-09-18 | 2000-09-18 | |
US60/233,133 | 2000-09-18 | ||
US60/233,617 | 2000-09-18 | ||
US23403400P | 2000-09-20 | 2000-09-20 | |
US23400900P | 2000-09-20 | 2000-09-20 | |
US23405200P | 2000-09-20 | 2000-09-20 | |
US60/234,052 | 2000-09-20 | ||
US60/234,009 | 2000-09-20 | ||
US60/234,034 | 2000-09-20 | ||
US23450900P | 2000-09-22 | 2000-09-22 | |
US23456700P | 2000-09-22 | 2000-09-22 | |
US60/234,509 | 2000-09-22 | ||
US60/234,567 | 2000-09-22 | ||
US23513400P | 2000-09-25 | 2000-09-25 | |
US23508200P | 2000-09-25 | 2000-09-25 | |
US23492300P | 2000-09-25 | 2000-09-25 | |
US23492400P | 2000-09-25 | 2000-09-25 | |
US23528000P | 2000-09-25 | 2000-09-25 | |
US23507700P | 2000-09-25 | 2000-09-25 | |
US60/235,082 | 2000-09-25 | ||
US60/235,077 | 2000-09-25 | ||
US60/235,280 | 2000-09-25 | ||
US60/235,134 | 2000-09-25 | ||
US60/234,923 | 2000-09-25 | ||
US60/234,924 | 2000-09-25 | ||
US23563700P | 2000-09-26 | 2000-09-26 | |
US23563800P | 2000-09-26 | 2000-09-26 | |
US60/235,638 | 2000-09-26 | ||
US60/235,637 | 2000-09-26 | ||
US23571100P | 2000-09-27 | 2000-09-27 | |
US23584000P | 2000-09-27 | 2000-09-27 | |
US23586300P | 2000-09-27 | 2000-09-27 | |
US23572000P | 2000-09-27 | 2000-09-27 | |
US60/235,840 | 2000-09-27 | ||
US60/235,720 | 2000-09-27 | ||
US60/235,711 | 2000-09-27 | ||
US60/235,863 | 2000-09-27 | ||
US23602800P | 2000-09-28 | 2000-09-28 | |
US23603400P | 2000-09-28 | 2000-09-28 | |
US23611100P | 2000-09-28 | 2000-09-28 | |
US23603200P | 2000-09-28 | 2000-09-28 | |
US23610900P | 2000-09-28 | 2000-09-28 | |
US23603300P | 2000-09-28 | 2000-09-28 | |
US60/236,034 | 2000-09-28 | ||
US60/236,033 | 2000-09-28 | ||
US60/236,028 | 2000-09-28 | ||
US60/236,111 | 2000-09-28 | ||
US60/236,109 | 2000-09-28 | ||
US60/236,032 | 2000-09-28 | ||
US23689100P | 2000-09-29 | 2000-09-29 | |
US23684200P | 2000-09-29 | 2000-09-29 | |
US60/236,891 | 2000-09-29 | ||
US60/236,842 | 2000-09-29 | ||
US23731600P | 2000-10-02 | 2000-10-02 | |
US23729500P | 2000-10-02 | 2000-10-02 | |
US23727800P | 2000-10-02 | 2000-10-02 | |
US23717300P | 2000-10-02 | 2000-10-02 | |
US23717200P | 2000-10-02 | 2000-10-02 | |
US23729400P | 2000-10-02 | 2000-10-02 | |
US60/237,295 | 2000-10-02 | ||
US60/237,294 | 2000-10-02 | ||
US60/237,278 | 2000-10-02 | ||
US60/237,173 | 2000-10-02 | ||
US60/237,316 | 2000-10-02 | ||
US60/237,172 | 2000-10-02 | ||
US23742500P | 2000-10-03 | 2000-10-03 | |
US23760400P | 2000-10-03 | 2000-10-03 | |
US23759800P | 2000-10-03 | 2000-10-03 | |
US23760600P | 2000-10-03 | 2000-10-03 | |
US23760800P | 2000-10-03 | 2000-10-03 | |
US60/237,604 | 2000-10-03 | ||
US60/237,598 | 2000-10-03 | ||
US60/237,606 | 2000-10-03 | ||
US60/237,425 | 2000-10-03 | ||
US60/237,608 | 2000-10-03 | ||
US24508400P | 2000-11-01 | 2000-11-01 | |
US24486700P | 2000-11-01 | 2000-11-01 | |
US60/245,084 | 2000-11-01 | ||
US60/244,867 | 2000-11-01 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001094629A2 true WO2001094629A2 (en) | 2001-12-13 |
WO2001094629A8 WO2001094629A8 (en) | 2002-05-16 |
WO2001094629A3 WO2001094629A3 (en) | 2003-09-04 |
Family
ID=27586968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/010838 WO2001094629A2 (en) | 2000-06-05 | 2001-05-30 | Cancer gene determination and therapeutic screening using signature gene sets |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1358349A2 (en) |
JP (1) | JP2004509612A (en) |
AU (1) | AU2001264559A1 (en) |
CA (1) | CA2411601A1 (en) |
WO (1) | WO2001094629A2 (en) |
Cited By (161)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002004513A2 (en) * | 2000-07-11 | 2002-01-17 | Incyte Genomics, Inc. | Down syndrome critical region 1-like 1 proteins |
WO2002012339A2 (en) * | 2000-08-03 | 2002-02-14 | Incyte Genomics, Inc. | Sequences for integrin alpha-8 |
WO2002016413A2 (en) * | 2000-08-24 | 2002-02-28 | Glaxosmithkline Biologicals S.A. | Cripto tumour polypeptide |
WO2001074900A3 (en) * | 2000-03-31 | 2002-05-02 | Aventis Pharm Prod Inc | Nuclear factor kb inducing factor |
WO2002044357A2 (en) * | 2000-11-30 | 2002-06-06 | Millennium Pharmaceuticals, Inc. | Methods of using 18903 to treat pain and pain-related disorders |
WO2002050286A2 (en) * | 2000-12-20 | 2002-06-27 | Pe Corporation (Ny) | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
WO2002059609A2 (en) * | 2000-12-08 | 2002-08-01 | Eos Biotechnology, Inc. | Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
WO2002062958A2 (en) * | 2001-02-08 | 2002-08-15 | Tularik Inc. | Prc17: an amplified cancer gene |
WO2002103017A1 (en) * | 2001-05-31 | 2002-12-27 | Chiba-Prefecture | Nucleic acids isolated in neuroblastoma |
EP1272224A1 (en) * | 2000-03-31 | 2003-01-08 | Gene Logic, Inc. | Gene expression profiles in esophageal tissue |
WO2003025199A2 (en) * | 2001-09-18 | 2003-03-27 | Millennium Pharmaceuticals, Inc. | Mid 4460, a human tyrosine phosphatase family member and uses therefor |
WO2003028750A1 (en) * | 2001-10-01 | 2003-04-10 | Duke University | Isolated grp94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same |
WO2003035837A2 (en) * | 2001-10-23 | 2003-05-01 | Sagres Discovery | Novel compositions and methods for cancer |
WO2003035857A1 (en) * | 2001-10-22 | 2003-05-01 | Bayer Healthcare Ag | Regulation of human nad-dependent alpha-glycerol-3-phosphate dehydrogenase |
WO2003046581A2 (en) * | 2001-11-27 | 2003-06-05 | Oxford Glycosciences (Uk) Ltd | Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers |
WO2003064451A2 (en) * | 2002-02-01 | 2003-08-07 | Beth Israel Deaconess Medical Center, Inc. | MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE |
EP1351967A2 (en) * | 2000-12-12 | 2003-10-15 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
WO2003085377A2 (en) * | 2002-04-01 | 2003-10-16 | Wyeth | Novel pancortin-pablo protein interactions and methods of use thereof |
EP1361433A2 (en) * | 2002-04-09 | 2003-11-12 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
EP1365247A1 (en) * | 2002-05-23 | 2003-11-26 | Bayer Ag | Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3) |
EP1365244A1 (en) * | 2002-05-23 | 2003-11-26 | Bayer Ag | Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2) |
WO2003105758A2 (en) * | 2002-06-12 | 2003-12-24 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
WO2003105783A2 (en) * | 2002-06-12 | 2003-12-24 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
WO2004003564A2 (en) * | 2002-06-26 | 2004-01-08 | Europroteome Ag | Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases |
WO2004007723A2 (en) * | 2002-07-17 | 2004-01-22 | Cambridge University Technical Services Limited | Genes |
EP1383543A1 (en) * | 2001-03-23 | 2004-01-28 | Agy Therapeutics, Inc. | Use of biomolecular targets in the treatment and visualization of brain tumors |
WO2004016784A1 (en) * | 2002-08-06 | 2004-02-26 | Genox Research, Inc. | Protease inhibitor |
WO2004022778A1 (en) * | 2002-09-05 | 2004-03-18 | Garvan Institute Of Medical Research | Methods of diagnosis and prognosis of ovarian cancer |
EP1402053A2 (en) * | 2001-06-05 | 2004-03-31 | Exelixis, Inc. | CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
WO2004031411A2 (en) * | 2002-09-30 | 2004-04-15 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human pancreatic cancers |
WO2004038411A3 (en) * | 2002-10-24 | 2004-06-17 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases |
WO2004058969A1 (en) * | 2002-12-24 | 2004-07-15 | Takeda Pharmaceutical Company Limited | Preventives/remedies for cancer |
US6777537B1 (en) | 1996-02-22 | 2004-08-17 | Forsyth Dental Infirmary For Children | Osteoclast proton pump subunit |
WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
WO2004074510A1 (en) * | 2003-02-18 | 2004-09-02 | Garvan Institute Of Medical Research | Methods of diagnosis and prognosis of pancreatic cancer |
WO2004076613A2 (en) * | 2003-02-26 | 2004-09-10 | Alexander Herr | Human nucleic acid sequences from carcinomas of the bladder |
WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
WO2004035082A3 (en) * | 2002-10-14 | 2004-09-23 | Develogen Ag | Proteins involved in the regulation of energy homeostasis |
FR2853909A1 (en) * | 2003-04-16 | 2004-10-22 | Galderma Res & Dev | Using polynucleotide probes based on the DPYSL3 gene (Dihydropyrimidinase-like 3), for diagnosis of psoriasis, or predisposition, and in screening for antipsoriatic agents |
EP1472376A2 (en) * | 2002-01-18 | 2004-11-03 | Millenium Pharmaceuticals, Inc. | Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo |
JP2004329211A (en) * | 2003-03-31 | 2004-11-25 | Veridex Llc | Colorectal cancer prognostics |
WO2004104224A2 (en) * | 2003-05-21 | 2004-12-02 | F. Hoffmann-La Roche Ag | Markers for lxr activation |
EP1496743A2 (en) * | 2002-04-05 | 2005-01-19 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
WO2005013893A2 (en) * | 2003-07-24 | 2005-02-17 | Avalon Pharmaceuticals, Inc. | Cancer related genes |
WO2005014818A1 (en) | 2003-08-08 | 2005-02-17 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
EP1510587A1 (en) * | 2002-05-21 | 2005-03-02 | Sysmex Corporation | Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers |
EP1512758A1 (en) * | 2003-08-27 | 2005-03-09 | Veridex, LLC | Colorectal cancer prognostics |
WO2005024055A1 (en) * | 2003-09-05 | 2005-03-17 | Garvan Institute Of Medical Research | Methods of diagnosis and prognosis of ovarian cancer ii |
US6887975B2 (en) | 1998-06-01 | 2005-05-03 | Agensys, Inc. | Peptides derived from STEAP1 |
US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
WO2005054508A2 (en) * | 2003-12-01 | 2005-06-16 | Ipsogen | Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters |
WO2005062055A2 (en) * | 2003-12-24 | 2005-07-07 | Cancer Research Technology Limited | Methods for detecting neoplasia and markers thereof |
WO2005076005A2 (en) * | 2004-01-30 | 2005-08-18 | Medizinische Universität Wien | A method for classifying a tumor cell sample based upon differential expression of at least two genes |
WO2005090991A1 (en) * | 2004-03-24 | 2005-09-29 | Oncotherapy Science, Inc. | Adam8 as tumor marker and therapeutic target for non-small cell lung cancer |
WO2004111273A3 (en) * | 2003-05-30 | 2005-10-06 | Genomic Health Inc | Gene expression markers for response to egfr inhibitor drugs |
US6953658B2 (en) | 2000-03-09 | 2005-10-11 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer |
WO2005097204A1 (en) * | 2004-04-09 | 2005-10-20 | Takeda Pharmaceutical Company Limited | Preventives/remedies for cancer |
EP1603514A2 (en) * | 2003-01-24 | 2005-12-14 | Bayer Pharmaceuticals Corporation | Expression profiles for colon cancer and methods of use |
WO2006002433A2 (en) * | 2004-06-24 | 2006-01-05 | Veridex, Llc | Methods and reagents for the detection of melanoma |
EP1557466A4 (en) * | 2002-09-27 | 2006-02-08 | Dainippon Sumitomo Pharma Co | Tumor antigen protein and utilization thereof |
WO2005090603A3 (en) * | 2004-03-23 | 2006-03-02 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancer |
WO2006027693A2 (en) * | 2004-09-09 | 2006-03-16 | Exonhit Therapeutics Sa | Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis |
US7041497B2 (en) | 2000-03-31 | 2006-05-09 | Aventis Pharmaceuticals Products Inc. | Nuclear factor κB inducing factor |
WO2006053442A1 (en) * | 2004-11-22 | 2006-05-26 | Diagnocure Inc. | Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis |
WO2006056080A1 (en) * | 2004-11-29 | 2006-06-01 | Diagnocure Inc. | Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis |
EP1666493A1 (en) * | 2000-06-02 | 2006-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids ancoding the same |
EP1666490A2 (en) * | 2000-07-25 | 2006-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1623993A3 (en) * | 1999-09-01 | 2006-06-07 | Genetech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1487991A4 (en) * | 2002-03-06 | 2006-06-14 | Avalon Pharmaceuticals | Cancer-linked gene as target for chemotherapy |
US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
EP1694866A2 (en) * | 2003-12-12 | 2006-08-30 | Bayer Pharmaceuticals Corporation | Gene expression profiles and methods of use |
US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
EP1709152A2 (en) * | 2003-12-15 | 2006-10-11 | The Regents Of The University Of California | Molecular signature of the pten tumor suppressor |
WO2006110760A2 (en) * | 2001-06-20 | 2006-10-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7144581B2 (en) | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
EP1735461A1 (en) * | 2004-04-06 | 2006-12-27 | The Regents Of The University Of California | Orphan receptor tyrosine kinase as a target in breast cancer |
US7172898B2 (en) | 2000-02-24 | 2007-02-06 | Agensys, Inc. | 103P2D6: tissue specific protein highly expressed in various cancers |
US7189524B1 (en) | 2002-11-25 | 2007-03-13 | Amgen, Inc. | Receptor ligands and methods of modulating receptors |
EP1774043A2 (en) * | 2004-05-28 | 2007-04-18 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
WO2007048978A2 (en) * | 2005-10-28 | 2007-05-03 | Biomerieux Sa | Method for detecting cancer |
WO2007074341A1 (en) * | 2005-12-28 | 2007-07-05 | Randox Laboratories Ltd | Detection of oesophageal cancer |
EP1812794A2 (en) * | 2004-10-13 | 2007-08-01 | A & G Pharmaceutical, Inc. | Autocrine growth factor receptors and methods |
US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US7264841B2 (en) | 2004-01-21 | 2007-09-04 | Linda Kalustian Lester | Savory gluten-free foods |
EP1828237A1 (en) * | 2004-12-22 | 2007-09-05 | Kim, Hyun-Kee | Human cancer suppressor gene, protein encoded therein, expression vector containing the same, and cell transformed by the vector |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
US7291719B2 (en) | 2000-07-25 | 2007-11-06 | Genentech, Inc. | PRO4332 antibodies |
JP2007531500A (en) * | 2003-07-17 | 2007-11-08 | パシフィック エッジ バイオテクノロジー リミティド | Gastric cancer detection marker |
WO2007128984A2 (en) * | 2006-04-06 | 2007-11-15 | Randox Laboratories Ltd | Breast cancer makers |
US7319006B2 (en) | 1998-06-01 | 2008-01-15 | Genentech, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US7323181B2 (en) | 1998-09-30 | 2008-01-29 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7329410B1 (en) | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
US7329502B2 (en) | 2002-04-25 | 2008-02-12 | The United States Of America As Represented By The Department Of Health And Human Services | ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) |
WO2008024009A1 (en) * | 2006-08-15 | 2008-02-28 | Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) | Transcriptional level of a timp3 gene in the form of a diagnosis marker of a non-small cell carcinoma of lung |
EP1860186A3 (en) * | 2003-03-10 | 2008-03-12 | Japan Science and Technology Corporation | Method for distinguishing mesenchymal stem cells using different markers |
US7358351B2 (en) | 2000-08-02 | 2008-04-15 | The Johns Hopkins University | Endothelial cell expression patterns |
WO2008045133A2 (en) * | 2006-03-03 | 2008-04-17 | Veridex, Llc | Molecular assay to predict recurrence of dukes' b colon cancer |
US7390882B2 (en) | 2001-06-20 | 2008-06-24 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7425624B1 (en) * | 2003-01-21 | 2008-09-16 | Mayo Foundation For Medical Education And Research | Sulfotransferase 1A3 sequence variants |
WO2008151110A2 (en) * | 2007-06-01 | 2008-12-11 | The University Of North Carolina At Chapel Hill | Molecular diagnosis and typing of lung cancer variants |
US7482129B2 (en) * | 2004-05-04 | 2009-01-27 | Institute Of Virology, Slovak Academy Of Sciences | MN/CA IX/CA9 and Renal Cancer Prognosis |
EP2021034A2 (en) * | 2006-04-28 | 2009-02-11 | Inis Biotech LLC | An isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells |
US7491390B2 (en) | 2004-10-15 | 2009-02-17 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
WO2009021680A1 (en) * | 2007-08-14 | 2009-02-19 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US7504222B2 (en) | 2001-10-31 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
EP1871793A4 (en) * | 2005-03-30 | 2009-04-22 | Kim Hyun Kee | Human protooncogene and protein encoded by same |
EP2052739A1 (en) * | 2006-08-16 | 2009-04-29 | Forerunner Pharma Research Co., Ltd. | Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient |
WO2009052567A1 (en) * | 2007-10-23 | 2009-04-30 | Clinical Genomics Pty. Ltd. | A method of diagnosing neoplasms - ii |
US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
WO2008154249A3 (en) * | 2007-06-08 | 2009-07-16 | Genentech Inc | Gene expression markers of tumor resistance to her2 inhibitor treatment |
WO2009101620A1 (en) * | 2008-02-11 | 2009-08-20 | Hadasit Medical Research Services & Development Limited | Colon cancer associated transcript 1 (ccat1) as a cancer marker |
US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
US7598355B2 (en) | 2000-03-24 | 2009-10-06 | Duke University | Characterization of GRP94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
US7604799B2 (en) | 2003-06-06 | 2009-10-20 | Medimmune, Llc | EphA4 Antibodies |
US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US7645441B2 (en) | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
US7662387B2 (en) | 2003-02-20 | 2010-02-16 | Seattle Genetics | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
WO2008114262A3 (en) * | 2007-03-21 | 2010-02-25 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer |
US7696336B2 (en) | 2002-08-16 | 2010-04-13 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
US7700274B2 (en) | 2000-12-22 | 2010-04-20 | Sagres Discovery, Inc. | Compositions and methods in cancer associated with altered expression of KCNJ9 |
US7700757B2 (en) | 2003-04-02 | 2010-04-20 | Giuliani Internaitonal Limited | Antisense oligonucleotides (ODN) against Smad7 and uses in medical field thereof |
US7736654B2 (en) | 2001-04-10 | 2010-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US7749977B2 (en) | 1997-11-12 | 2010-07-06 | Quark Pharmaceuticals, Inc. | Therapeutic modulation of the Fas pathway |
EP2177614A3 (en) * | 2005-05-02 | 2010-08-11 | Toray Industries, Inc. | Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer |
US7820447B2 (en) | 2000-12-22 | 2010-10-26 | Sagres Discovery Inc. | Compositions and methods for cancer |
AU2004264952B2 (en) * | 2003-08-14 | 2010-12-16 | Exelixis, Inc. | PRKCs as modifiers of the beta catenin pathway and methods of use |
EP2269628A2 (en) | 2002-05-29 | 2011-01-05 | DeveloGen Aktiengesellschaft | Pancreas-specific proteins |
EP2270501A3 (en) * | 2002-09-30 | 2011-01-19 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
WO2011009036A1 (en) * | 2009-07-16 | 2011-01-20 | Soymeds, Inc. | Soybean derived human thyroglobulin, methods of producing and applications thereof |
WO2011013729A1 (en) | 2009-07-30 | 2011-02-03 | オンコセラピー・サイエンス株式会社 | Fused imidazole derivative having ttk inhibitory action |
US7884179B2 (en) | 2001-09-06 | 2011-02-08 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
US7892730B2 (en) | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
US7901693B2 (en) | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
EP2267158A3 (en) * | 2004-05-11 | 2011-04-06 | Ganymed Pharmaceuticals AG | Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
US7947459B2 (en) | 1998-06-01 | 2011-05-24 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
EP2333112A2 (en) | 2004-02-20 | 2011-06-15 | Veridex, LLC | Breast cancer prognostics |
US8008442B2 (en) | 2004-04-22 | 2011-08-30 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US8067546B2 (en) | 2005-04-19 | 2011-11-29 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
US8211434B2 (en) | 2008-11-26 | 2012-07-03 | Allergan, Inc. | KLK-13 antibody inhibitor for treating dry eye |
US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
EP2518166A3 (en) * | 2005-05-20 | 2013-01-09 | Veridex, LLC | Thyroid fine needle aspiration molecular assay |
US20130023441A1 (en) * | 2004-06-04 | 2013-01-24 | Biotheranostics, Inc. | Identification of Tumors |
US8436147B2 (en) | 2006-10-27 | 2013-05-07 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
US8535914B2 (en) * | 2005-01-21 | 2013-09-17 | Canon Kabushiki Kaisha | Probe, probe set and information acquisition method using the same |
US8637642B2 (en) | 2010-09-29 | 2014-01-28 | Seattle Genetics, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
US8647826B2 (en) | 2001-03-14 | 2014-02-11 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer |
US8663642B2 (en) | 2003-02-20 | 2014-03-04 | Seattle Genetics, Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders |
US8716021B2 (en) | 2005-09-07 | 2014-05-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of replicators to prevent gene silencing |
AU2012200098B2 (en) * | 2004-05-11 | 2014-05-08 | Ganymed Pharmaceuticals Ag | Identification of surface-associated antigens for tumour diagnosis and therapy |
US9120854B2 (en) | 2008-04-11 | 2015-09-01 | Seattle Genetics, Inc. | Detection and treatment of pancreatic, ovarian and other cancers |
US9260499B2 (en) | 2008-10-20 | 2016-02-16 | Sapporo Medical University | Tumor antigen peptide and use thereof |
WO2016083360A1 (en) * | 2014-11-25 | 2016-06-02 | Ait Austrian Institute Of Technology Gmbh | Diagnosis of lung cancer |
AU2014208220B2 (en) * | 2004-05-11 | 2016-08-04 | Ganymed Pharmaceuticals Ag | Identification of surface-associated antigens for tumor diagnosis and therapy |
US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
US9670553B2 (en) | 2004-06-04 | 2017-06-06 | Biotheranostics, Inc. | Determining tumor origin |
JP2021003136A (en) * | 2015-05-15 | 2021-01-14 | 国立大学法人高知大学 | Pancreatic cancer diagnostic kit |
US11180571B2 (en) | 2017-04-03 | 2021-11-23 | Hoffmann-La Roche Inc. | Antibodies binding to STEAP-1 |
US11319526B2 (en) | 2008-05-02 | 2022-05-03 | Seagen Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
US11430544B2 (en) | 2005-06-03 | 2022-08-30 | Biotheranostics, Inc. | Identification of tumors and tissues |
US11820827B2 (en) | 2019-12-30 | 2023-11-21 | Seagen Inc. | Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006174731A (en) * | 2004-12-21 | 2006-07-06 | Seikagaku Kogyo Co Ltd | Translocation agent and method for detecting canceration of tissue |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019369A1 (en) * | 1994-01-14 | 1995-07-20 | Vanderbilt University | Method for detection and treatment of breast cancer |
US5882874A (en) * | 1998-02-27 | 1999-03-16 | The Trustees Of Columbia University In The City Of New York | Reciprocal subtraction differential display |
WO1999050278A1 (en) * | 1998-03-31 | 1999-10-07 | Genzyme Corporation | Compositions and methods for the identification of lung tumor cells |
-
2001
- 2001-05-30 CA CA002411601A patent/CA2411601A1/en not_active Abandoned
- 2001-05-30 AU AU2001264559A patent/AU2001264559A1/en not_active Abandoned
- 2001-05-30 WO PCT/US2001/010838 patent/WO2001094629A2/en not_active Application Discontinuation
- 2001-05-30 JP JP2002502169A patent/JP2004509612A/en not_active Withdrawn
- 2001-05-30 EP EP01938990A patent/EP1358349A2/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019369A1 (en) * | 1994-01-14 | 1995-07-20 | Vanderbilt University | Method for detection and treatment of breast cancer |
US5882874A (en) * | 1998-02-27 | 1999-03-16 | The Trustees Of Columbia University In The City Of New York | Reciprocal subtraction differential display |
WO1999050278A1 (en) * | 1998-03-31 | 1999-10-07 | Genzyme Corporation | Compositions and methods for the identification of lung tumor cells |
Non-Patent Citations (6)
Title |
---|
CHENG L ET AL: "Characterisations of taxol-induced apoptosis and altered gene expression in human breast cancer cells." CELLULAR PHARMACOLOGY, vol. 2, no. 6, 1995, pages 249-257, XP008013734 ISSN: 1351-3214 * |
DATABASE EBI [Online] 3 August 1996 (1996-08-03) HILLIER, L. ET AL.: "ze23c03.s1 Soares fetal heart, H. sapiens cDNA clone, mRNA sequence;" retrieved from EMBL Database accession no. AA011199 XP002230815 * |
HESS J ET AL: "Application of differential cDNA screening techniques to the identification of unique gene expression in tumours and lymphocytes" CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 10, no. 2, April 1998 (1998-04), pages 125-130, XP004327175 ISSN: 0952-7915 * |
KURDISTANI SIAVASH K ET AL: "Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage." CANCER RESEARCH, vol. 58, no. 19, 1 October 1998 (1998-10-01), pages 4439-4444, XP001109678 ISSN: 0008-5472 * |
SIAVOSHIAN S ET AL: "Subtractive hybridization and differential screening identified two genes differentially expressed after induction of in vitro (atypical) terminal differentiation in the NSCLC-N6 cell line by a marine substance (bistramide K)." ANTICANCER RESEARCH., vol. 19, no. 6b, November 1999 (1999-11), pages 5361-5366, XP008013799 ISSN: 0250-7005 * |
VIETOR I ET AL: "In search of differentially expressed genes and proteins" BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1359, no. 3, 12 December 1997 (1997-12-12), pages 187-199, XP004277797 ISSN: 0167-4889 * |
Cited By (347)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777537B1 (en) | 1996-02-22 | 2004-08-17 | Forsyth Dental Infirmary For Children | Osteoclast proton pump subunit |
US7749977B2 (en) | 1997-11-12 | 2010-07-06 | Quark Pharmaceuticals, Inc. | Therapeutic modulation of the Fas pathway |
US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
US7585506B2 (en) | 1998-03-18 | 2009-09-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US7727533B2 (en) | 1998-06-01 | 2010-06-01 | Genentech, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US6887975B2 (en) | 1998-06-01 | 2005-05-03 | Agensys, Inc. | Peptides derived from STEAP1 |
US7575749B2 (en) | 1998-06-01 | 2009-08-18 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US7485299B2 (en) | 1998-06-01 | 2009-02-03 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US7319006B2 (en) | 1998-06-01 | 2008-01-15 | Genentech, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US7947459B2 (en) | 1998-06-01 | 2011-05-24 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US7662386B2 (en) | 1998-09-30 | 2010-02-16 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
US7323181B2 (en) | 1998-09-30 | 2008-01-29 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7901693B2 (en) | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7329410B1 (en) | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
US7655249B2 (en) | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7368119B2 (en) | 1998-09-30 | 2008-05-06 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US8053551B2 (en) | 1999-06-01 | 2011-11-08 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses therefor |
US8241626B2 (en) | 1999-06-01 | 2012-08-14 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
EP1623993A3 (en) * | 1999-09-01 | 2006-06-07 | Genetech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7771968B2 (en) | 1999-10-28 | 2010-08-10 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
US7928212B2 (en) | 1999-10-28 | 2011-04-19 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
US7749505B2 (en) | 1999-12-17 | 2010-07-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US7199220B2 (en) | 2000-02-24 | 2007-04-03 | Agensys, Inc. | 103P2D6: tissue specific protein highly expressed in various cancers |
US7172898B2 (en) | 2000-02-24 | 2007-02-06 | Agensys, Inc. | 103P2D6: tissue specific protein highly expressed in various cancers |
US6953658B2 (en) | 2000-03-09 | 2005-10-11 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer |
US7235649B2 (en) | 2000-03-24 | 2007-06-26 | Duke University | Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same |
US7598355B2 (en) | 2000-03-24 | 2009-10-06 | Duke University | Characterization of GRP94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
WO2001074900A3 (en) * | 2000-03-31 | 2002-05-02 | Aventis Pharm Prod Inc | Nuclear factor kb inducing factor |
EP1272224A1 (en) * | 2000-03-31 | 2003-01-08 | Gene Logic, Inc. | Gene expression profiles in esophageal tissue |
US8623831B2 (en) | 2000-03-31 | 2014-01-07 | Aventis Pharmaceuticals Inc. | Nuclear factor κB inducing factor |
US8642739B2 (en) | 2000-03-31 | 2014-02-04 | Aventis Pharmaceuticals Inc. | Nuclear factor κB inducing factor |
EP1272224A4 (en) * | 2000-03-31 | 2004-09-29 | Gene Logic Inc | Gene expression profiles in esophageal tissue |
US7972844B2 (en) | 2000-03-31 | 2011-07-05 | Aventis Pharmaceuticals Inc. | Nuclear factor κB inducing factor |
US7041497B2 (en) | 2000-03-31 | 2006-05-09 | Aventis Pharmaceuticals Products Inc. | Nuclear factor κB inducing factor |
EP1666493A1 (en) * | 2000-06-02 | 2006-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids ancoding the same |
WO2002004513A3 (en) * | 2000-07-11 | 2003-04-24 | Incyte Genomics Inc | Down syndrome critical region 1-like 1 proteins |
WO2002004513A2 (en) * | 2000-07-11 | 2002-01-17 | Incyte Genomics, Inc. | Down syndrome critical region 1-like 1 proteins |
US7291719B2 (en) | 2000-07-25 | 2007-11-06 | Genentech, Inc. | PRO4332 antibodies |
EP1666490A2 (en) * | 2000-07-25 | 2006-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7335731B2 (en) | 2000-07-25 | 2008-02-26 | Genentech, Inc. | PRO4332 polypeptides |
EP1666490A3 (en) * | 2000-07-25 | 2006-11-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7358351B2 (en) | 2000-08-02 | 2008-04-15 | The Johns Hopkins University | Endothelial cell expression patterns |
US7402660B2 (en) | 2000-08-02 | 2008-07-22 | The Johns Hopkins University | Endothelial cell expression patterns |
WO2002012339A2 (en) * | 2000-08-03 | 2002-02-14 | Incyte Genomics, Inc. | Sequences for integrin alpha-8 |
WO2002012339A3 (en) * | 2000-08-03 | 2002-06-13 | Incyte Genomics Inc | Sequences for integrin alpha-8 |
US7439320B2 (en) | 2000-08-24 | 2008-10-21 | Glaxosmith Kline Biologicals S.A. | Cripto tumour polypeptide |
WO2002016413A2 (en) * | 2000-08-24 | 2002-02-28 | Glaxosmithkline Biologicals S.A. | Cripto tumour polypeptide |
WO2002016413A3 (en) * | 2000-08-24 | 2002-12-05 | Smithkline Beecham Biolog | Cripto tumour polypeptide |
US7144581B2 (en) | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
WO2002044357A2 (en) * | 2000-11-30 | 2002-06-06 | Millennium Pharmaceuticals, Inc. | Methods of using 18903 to treat pain and pain-related disorders |
US7081344B2 (en) | 2000-11-30 | 2006-07-25 | Millennium Pharmaceuticals, Inc. | Methods for screening compounds that bind human COE-2 |
WO2002044357A3 (en) * | 2000-11-30 | 2003-02-13 | Millennium Pharm Inc | Methods of using 18903 to treat pain and pain-related disorders |
WO2002059609A2 (en) * | 2000-12-08 | 2002-08-01 | Eos Biotechnology, Inc. | Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
WO2002059609A3 (en) * | 2000-12-08 | 2004-02-12 | Eos Biotechnology Inc | Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
EP1351967A2 (en) * | 2000-12-12 | 2003-10-15 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
EP1351967A4 (en) * | 2000-12-12 | 2004-12-22 | Corixa Corp | Compositions and methods for the therapy and diagnosis of lung cancer |
WO2002050286A3 (en) * | 2000-12-20 | 2003-03-13 | Pe Corp Ny | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
WO2002050286A2 (en) * | 2000-12-20 | 2002-06-27 | Pe Corporation (Ny) | Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
US7700274B2 (en) | 2000-12-22 | 2010-04-20 | Sagres Discovery, Inc. | Compositions and methods in cancer associated with altered expression of KCNJ9 |
US7820447B2 (en) | 2000-12-22 | 2010-10-26 | Sagres Discovery Inc. | Compositions and methods for cancer |
US7645441B2 (en) | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
US7892730B2 (en) | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
WO2002062958A2 (en) * | 2001-02-08 | 2002-08-15 | Tularik Inc. | Prc17: an amplified cancer gene |
WO2002062958A3 (en) * | 2001-02-08 | 2003-04-10 | Tularik Inc | Prc17: an amplified cancer gene |
US7488479B2 (en) | 2001-03-14 | 2009-02-10 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer |
US7759474B2 (en) | 2001-03-14 | 2010-07-20 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer |
US8647826B2 (en) | 2001-03-14 | 2014-02-11 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer |
US7968090B2 (en) | 2001-03-14 | 2011-06-28 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer |
US7834156B2 (en) | 2001-03-14 | 2010-11-16 | Agensys, Inc. | 125P5C8: tissue specific protein highly expressed in various cancers |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
US7928196B2 (en) | 2001-03-14 | 2011-04-19 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer |
EP1383543A1 (en) * | 2001-03-23 | 2004-01-28 | Agy Therapeutics, Inc. | Use of biomolecular targets in the treatment and visualization of brain tumors |
EP1383543A4 (en) * | 2001-03-23 | 2006-06-21 | Agy Therapeutics Inc | Use of biomolecular targets in the treatment and visualization of brain tumors |
US7736654B2 (en) | 2001-04-10 | 2010-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
WO2002103017A1 (en) * | 2001-05-31 | 2002-12-27 | Chiba-Prefecture | Nucleic acids isolated in neuroblastoma |
EP1402053A2 (en) * | 2001-06-05 | 2004-03-31 | Exelixis, Inc. | CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
EP1402053A4 (en) * | 2001-06-05 | 2005-05-11 | Exelixis Inc | CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
EP2000482A1 (en) * | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US8728480B2 (en) | 2001-06-20 | 2014-05-20 | Genetech, Inc. | Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereof |
US8398982B2 (en) | 2001-06-20 | 2013-03-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2006110760A2 (en) * | 2001-06-20 | 2006-10-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7390882B2 (en) | 2001-06-20 | 2008-06-24 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2006110760A3 (en) * | 2001-06-20 | 2007-03-08 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
US7547768B2 (en) | 2001-06-20 | 2009-06-16 | Genentech, Inc. | Anti-TAT 113 antibodies |
US8278042B2 (en) | 2001-06-20 | 2012-10-02 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7915393B2 (en) | 2001-08-24 | 2011-03-29 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
US7947276B2 (en) | 2001-09-06 | 2011-05-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US7884179B2 (en) | 2001-09-06 | 2011-02-08 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
US7939503B2 (en) | 2001-09-06 | 2011-05-10 | Agensys, Inc. | Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA |
US8013135B2 (en) | 2001-09-06 | 2011-09-06 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US9029516B2 (en) | 2001-09-06 | 2015-05-12 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US7157240B2 (en) | 2001-09-18 | 2007-01-02 | Bayer Healthcare Ag | MID 4460, a human tyrosine phosphatase family member and uses therefor |
WO2003025199A3 (en) * | 2001-09-18 | 2003-10-30 | Millennium Pharm Inc | Mid 4460, a human tyrosine phosphatase family member and uses therefor |
WO2003025199A2 (en) * | 2001-09-18 | 2003-03-27 | Millennium Pharmaceuticals, Inc. | Mid 4460, a human tyrosine phosphatase family member and uses therefor |
WO2003028750A1 (en) * | 2001-10-01 | 2003-04-10 | Duke University | Isolated grp94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same |
WO2003035857A1 (en) * | 2001-10-22 | 2003-05-01 | Bayer Healthcare Ag | Regulation of human nad-dependent alpha-glycerol-3-phosphate dehydrogenase |
WO2003035837A2 (en) * | 2001-10-23 | 2003-05-01 | Sagres Discovery | Novel compositions and methods for cancer |
WO2003035837A3 (en) * | 2001-10-23 | 2004-02-26 | Sagres Discovery | Novel compositions and methods for cancer |
US7504222B2 (en) | 2001-10-31 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
WO2003046581A2 (en) * | 2001-11-27 | 2003-06-05 | Oxford Glycosciences (Uk) Ltd | Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers |
AU2002343109B2 (en) * | 2001-11-27 | 2008-06-12 | Ucb Pharma S.A. | Methods for diagnosis and treatment of epithelial-derived cancers, such as colorectal cancers and kidney cancers |
WO2003046581A3 (en) * | 2001-11-27 | 2004-04-08 | Oxford Glycosciences Uk Ltd | Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers |
EP1472376A4 (en) * | 2002-01-18 | 2007-03-21 | Millennium Pharm Inc | Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo |
EP1472376A2 (en) * | 2002-01-18 | 2004-11-03 | Millenium Pharmaceuticals, Inc. | Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo |
WO2003064451A2 (en) * | 2002-02-01 | 2003-08-07 | Beth Israel Deaconess Medical Center, Inc. | MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE |
WO2003064451A3 (en) * | 2002-02-01 | 2003-09-04 | Beth Israel Hospital | MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE |
EP1487991A4 (en) * | 2002-03-06 | 2006-06-14 | Avalon Pharmaceuticals | Cancer-linked gene as target for chemotherapy |
WO2003085377A3 (en) * | 2002-04-01 | 2004-12-02 | Wyeth Corp | Novel pancortin-pablo protein interactions and methods of use thereof |
WO2003085377A2 (en) * | 2002-04-01 | 2003-10-16 | Wyeth | Novel pancortin-pablo protein interactions and methods of use thereof |
EP1496743A2 (en) * | 2002-04-05 | 2005-01-19 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
EP1496743A4 (en) * | 2002-04-05 | 2006-06-21 | Corixa Corp | Compositions and methods for the therapy and diagnosis of lung cancer |
EP1361433A3 (en) * | 2002-04-09 | 2005-02-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
EP1361433A2 (en) * | 2002-04-09 | 2003-11-12 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
US7981610B2 (en) | 2002-04-25 | 2011-07-19 | The United States Of America As Represented By The Department Of Health And Human Services | ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) |
US8748114B2 (en) | 2002-04-25 | 2014-06-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) |
US7329502B2 (en) | 2002-04-25 | 2008-02-12 | The United States Of America As Represented By The Department Of Health And Human Services | ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) |
EP1510587A1 (en) * | 2002-05-21 | 2005-03-02 | Sysmex Corporation | Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers |
EP1510587A4 (en) * | 2002-05-21 | 2007-11-14 | Sysmex Corp | Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers |
US8076080B2 (en) | 2002-05-21 | 2011-12-13 | Sysmex Corporation | Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers |
EP1365247A1 (en) * | 2002-05-23 | 2003-11-26 | Bayer Ag | Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3) |
EP1365244A1 (en) * | 2002-05-23 | 2003-11-26 | Bayer Ag | Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2) |
EP2275118A2 (en) | 2002-05-29 | 2011-01-19 | DeveloGen Aktiengesellschaft | Pancreas-specific proteins |
EP2269628A2 (en) | 2002-05-29 | 2011-01-05 | DeveloGen Aktiengesellschaft | Pancreas-specific proteins |
WO2003105783A2 (en) * | 2002-06-12 | 2003-12-24 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
WO2003105758A2 (en) * | 2002-06-12 | 2003-12-24 | Avalon Pharmaceuticals, Inc. | Cancer-linked gene as target for chemotherapy |
WO2003105783A3 (en) * | 2002-06-12 | 2006-03-30 | Avalon Pharmaceuticals | Cancer-linked gene as target for chemotherapy |
WO2003105758A3 (en) * | 2002-06-12 | 2004-02-26 | Avalon Pharmaceuticals | Cancer-linked gene as target for chemotherapy |
WO2004003564A3 (en) * | 2002-06-26 | 2004-12-29 | Europroteome Ag | Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases |
WO2004003564A2 (en) * | 2002-06-26 | 2004-01-08 | Europroteome Ag | Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases |
US7488803B2 (en) | 2002-07-17 | 2009-02-10 | Cambridge Enterprise Limited | Antibodies to the extracellular domain of human Fragilis polypeptide and methods of making said antibodies |
WO2004007723A3 (en) * | 2002-07-17 | 2004-04-01 | Univ Cambridge Tech | Genes |
WO2004007723A2 (en) * | 2002-07-17 | 2004-01-22 | Cambridge University Technical Services Limited | Genes |
WO2004016784A1 (en) * | 2002-08-06 | 2004-02-26 | Genox Research, Inc. | Protease inhibitor |
US8426571B2 (en) | 2002-08-16 | 2013-04-23 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 202P5A5 useful in treatment and detection of cancer |
US7696336B2 (en) | 2002-08-16 | 2010-04-13 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
US8057996B2 (en) | 2002-08-16 | 2011-11-15 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 202P5A5 useful in treatment and detection of cancer |
US8604169B2 (en) | 2002-08-16 | 2013-12-10 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
WO2004022778A1 (en) * | 2002-09-05 | 2004-03-18 | Garvan Institute Of Medical Research | Methods of diagnosis and prognosis of ovarian cancer |
EP1557466A4 (en) * | 2002-09-27 | 2006-02-08 | Dainippon Sumitomo Pharma Co | Tumor antigen protein and utilization thereof |
US7700108B2 (en) | 2002-09-27 | 2010-04-20 | Dainippon Sumitomo Pharma Co., Ltd. | Tumor antigen protein and use thereof |
EP2270212A3 (en) * | 2002-09-30 | 2011-06-29 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
CN1703524B (en) * | 2002-09-30 | 2010-04-07 | 肿瘤疗法科学股份有限公司 | Genes and polypeptides relating to human pancreatic cancer |
WO2004031411A3 (en) * | 2002-09-30 | 2004-09-30 | Oncotherapy Science Inc | Genes and polypeptides relating to human pancreatic cancers |
EP2270213A3 (en) * | 2002-09-30 | 2011-06-29 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
WO2004031411A2 (en) * | 2002-09-30 | 2004-04-15 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human pancreatic cancers |
WO2004031412A3 (en) * | 2002-09-30 | 2004-07-15 | Oncotherapy Science Inc | Method for diagnosing pancreatic cancer |
EP2270501A3 (en) * | 2002-09-30 | 2011-01-19 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
EP2270219A3 (en) * | 2002-09-30 | 2011-07-27 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
EP2270217A3 (en) * | 2002-09-30 | 2011-07-27 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
EP2009117A3 (en) * | 2002-09-30 | 2009-03-18 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
WO2004031412A2 (en) * | 2002-09-30 | 2004-04-15 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
US7601826B2 (en) | 2002-09-30 | 2009-10-13 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human pancreatic cancers |
US7943730B2 (en) | 2002-09-30 | 2011-05-17 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human pancreatic cancers |
EP2270502A3 (en) * | 2002-09-30 | 2011-01-26 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
WO2004035082A3 (en) * | 2002-10-14 | 2004-09-23 | Develogen Ag | Proteins involved in the regulation of energy homeostasis |
WO2004038411A3 (en) * | 2002-10-24 | 2004-06-17 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases |
US7189524B1 (en) | 2002-11-25 | 2007-03-13 | Amgen, Inc. | Receptor ligands and methods of modulating receptors |
WO2004058969A1 (en) * | 2002-12-24 | 2004-07-15 | Takeda Pharmaceutical Company Limited | Preventives/remedies for cancer |
US7745185B1 (en) | 2003-01-21 | 2010-06-29 | Mayo Foundation For Medical Education And Research | Sulfotransferase 1A3 sequence variants |
US7425624B1 (en) * | 2003-01-21 | 2008-09-16 | Mayo Foundation For Medical Education And Research | Sulfotransferase 1A3 sequence variants |
EP1603514A4 (en) * | 2003-01-24 | 2007-08-22 | Bayer Pharmaceuticals Corp | Expression profiles for colon cancer and methods of use |
EP1603514A2 (en) * | 2003-01-24 | 2005-12-14 | Bayer Pharmaceuticals Corporation | Expression profiles for colon cancer and methods of use |
WO2004070062A3 (en) * | 2003-02-04 | 2004-11-18 | Wyeth Corp | Compositions and methods for diagnosing and treating cancers |
WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
WO2004074510A1 (en) * | 2003-02-18 | 2004-09-02 | Garvan Institute Of Medical Research | Methods of diagnosis and prognosis of pancreatic cancer |
EP1599603A1 (en) * | 2003-02-18 | 2005-11-30 | Garvan Institute Of Medical Research | Methods of diagnosis and prognosis of pancreatic cancer |
EP1599603A4 (en) * | 2003-02-18 | 2007-08-22 | Garvan Inst Med Res | Methods of diagnosis and prognosis of pancreatic cancer |
US8609104B2 (en) | 2003-02-20 | 2013-12-17 | Seattle Genetics, Inc. | Treatment of B-cell cancers with anti-CD70 antibody-drug conjugates |
US8535678B2 (en) | 2003-02-20 | 2013-09-17 | Seattle Genetics, Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
US7662387B2 (en) | 2003-02-20 | 2010-02-16 | Seattle Genetics | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
US8663642B2 (en) | 2003-02-20 | 2014-03-04 | Seattle Genetics, Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders |
WO2004076613A3 (en) * | 2003-02-26 | 2005-01-06 | Alexander Herr | Human nucleic acid sequences from carcinomas of the bladder |
WO2004076613A2 (en) * | 2003-02-26 | 2004-09-10 | Alexander Herr | Human nucleic acid sequences from carcinomas of the bladder |
WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
EP1860186A3 (en) * | 2003-03-10 | 2008-03-12 | Japan Science and Technology Corporation | Method for distinguishing mesenchymal stem cells using different markers |
AU2004201348B2 (en) * | 2003-03-31 | 2008-04-10 | Ortho-Clinical Diagnostics, Inc. | Colorectal cancer prognostics |
JP2004329211A (en) * | 2003-03-31 | 2004-11-25 | Veridex Llc | Colorectal cancer prognostics |
KR101088583B1 (en) * | 2003-03-31 | 2011-12-05 | 베리덱스 엘엘씨 | Colorectal cancer prognostics |
EP1526186A2 (en) * | 2003-03-31 | 2005-04-27 | Veridex LLC | Colorectal cancer prognostics |
EP1526186A3 (en) * | 2003-03-31 | 2005-08-17 | Veridex LLC | Colorectal cancer prognostics |
US9382541B2 (en) | 2003-04-02 | 2016-07-05 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field |
US8648186B2 (en) | 2003-04-02 | 2014-02-11 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field |
US9096854B1 (en) | 2003-04-02 | 2015-08-04 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field |
US9279126B2 (en) | 2003-04-02 | 2016-03-08 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field |
US8907078B2 (en) | 2003-04-02 | 2014-12-09 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field |
US7700757B2 (en) | 2003-04-02 | 2010-04-20 | Giuliani Internaitonal Limited | Antisense oligonucleotides (ODN) against Smad7 and uses in medical field thereof |
US9006418B2 (en) | 2003-04-02 | 2015-04-14 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field |
US8106182B2 (en) | 2003-04-02 | 2012-01-31 | Giuliani International Limited | Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field |
US9518264B2 (en) | 2003-04-02 | 2016-12-13 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field |
US10036022B2 (en) | 2003-04-02 | 2018-07-31 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field |
US9605264B2 (en) | 2003-04-02 | 2017-03-28 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field |
US7807818B2 (en) | 2003-04-02 | 2010-10-05 | Giuliani International Limited | Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field |
US10738309B2 (en) | 2003-04-02 | 2020-08-11 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field |
US10633660B2 (en) | 2003-04-02 | 2020-04-28 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field |
US9951334B2 (en) | 2003-04-02 | 2018-04-24 | Nogra Pharma Limited | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field |
WO2004094660A3 (en) * | 2003-04-16 | 2004-12-29 | Galderma Res & Dev | Use of gene dpysl3 as a marker of psoriasis |
FR2853909A1 (en) * | 2003-04-16 | 2004-10-22 | Galderma Res & Dev | Using polynucleotide probes based on the DPYSL3 gene (Dihydropyrimidinase-like 3), for diagnosis of psoriasis, or predisposition, and in screening for antipsoriatic agents |
WO2004094660A2 (en) * | 2003-04-16 | 2004-11-04 | Galderma Research & Development, S.N.C. | Use of gene dpysl3 as a marker of psoriasis |
WO2004104224A2 (en) * | 2003-05-21 | 2004-12-02 | F. Hoffmann-La Roche Ag | Markers for lxr activation |
WO2004104224A3 (en) * | 2003-05-21 | 2005-03-31 | Hoffmann La Roche | Markers for lxr activation |
WO2004111273A3 (en) * | 2003-05-30 | 2005-10-06 | Genomic Health Inc | Gene expression markers for response to egfr inhibitor drugs |
US7604799B2 (en) | 2003-06-06 | 2009-10-20 | Medimmune, Llc | EphA4 Antibodies |
JP2011250795A (en) * | 2003-07-17 | 2011-12-15 | Pacific Edge Biotechnology Ltd | Marker for detection of gastric cancer |
JP2014236737A (en) * | 2003-07-17 | 2014-12-18 | パシフィック エッジ バイオテクノロジー リミティド | Markers for detection of gastric cancer |
JP2007531500A (en) * | 2003-07-17 | 2007-11-08 | パシフィック エッジ バイオテクノロジー リミティド | Gastric cancer detection marker |
EP2325338A3 (en) * | 2003-07-17 | 2011-10-12 | Pacific Edge Limited | Markers for detection of gastric cancer |
AU2004260083B2 (en) * | 2003-07-17 | 2011-04-07 | Pacific Edge Limited | Markers for detection of gastric cancer |
EP2305833A3 (en) * | 2003-07-17 | 2012-02-01 | Pacific Edge Limited | Markers for detection of gastric cancer |
US10179935B2 (en) | 2003-07-17 | 2019-01-15 | Pacific Edge Limited | Markers for detection of gastric cancer |
WO2005013893A2 (en) * | 2003-07-24 | 2005-02-17 | Avalon Pharmaceuticals, Inc. | Cancer related genes |
WO2005013893A3 (en) * | 2003-07-24 | 2006-10-05 | Avalon Pharmaceuticals | Cancer related genes |
EP2311468A1 (en) | 2003-08-08 | 2011-04-20 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
WO2005014818A1 (en) | 2003-08-08 | 2005-02-17 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
AU2004264952B2 (en) * | 2003-08-14 | 2010-12-16 | Exelixis, Inc. | PRKCs as modifiers of the beta catenin pathway and methods of use |
EP1512758A1 (en) * | 2003-08-27 | 2005-03-09 | Veridex, LLC | Colorectal cancer prognostics |
JP2006101701A (en) * | 2003-08-28 | 2006-04-20 | Veridex Llc | Forecast of prognosis of colorectal cancer |
CN1637151A (en) * | 2003-08-28 | 2005-07-13 | 维里德克斯有限责任公司 | Colorectal cancer prognostics |
AU2004205270B2 (en) * | 2003-08-28 | 2009-01-22 | Veridex, Llc | Colorectal cancer prognostics |
CN1637151B (en) * | 2003-08-28 | 2013-07-17 | 维里德克斯有限责任公司 | Colorectal cancer prognostics |
WO2005024055A1 (en) * | 2003-09-05 | 2005-03-17 | Garvan Institute Of Medical Research | Methods of diagnosis and prognosis of ovarian cancer ii |
WO2005054508A2 (en) * | 2003-12-01 | 2005-06-16 | Ipsogen | Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters |
WO2005054508A3 (en) * | 2003-12-01 | 2006-05-18 | Ipsogen | Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters |
EP1694866A4 (en) * | 2003-12-12 | 2007-12-26 | Bayer Pharmaceuticals Corp | Gene expression profiles and methods of use |
EP1694866A2 (en) * | 2003-12-12 | 2006-08-30 | Bayer Pharmaceuticals Corporation | Gene expression profiles and methods of use |
EP1709152A2 (en) * | 2003-12-15 | 2006-10-11 | The Regents Of The University Of California | Molecular signature of the pten tumor suppressor |
AU2004298604B2 (en) * | 2003-12-15 | 2010-09-23 | The Regents Of The University Of California | Molecular signature of the PTEN tumor suppressor |
EP1709152A4 (en) * | 2003-12-15 | 2007-11-07 | Univ California | Molecular signature of the pten tumor suppressor |
WO2005062055A2 (en) * | 2003-12-24 | 2005-07-07 | Cancer Research Technology Limited | Methods for detecting neoplasia and markers thereof |
WO2005062055A3 (en) * | 2003-12-24 | 2005-10-13 | Cancer Rec Tech Ltd | Methods for detecting neoplasia and markers thereof |
US7264841B2 (en) | 2004-01-21 | 2007-09-04 | Linda Kalustian Lester | Savory gluten-free foods |
WO2005076005A2 (en) * | 2004-01-30 | 2005-08-18 | Medizinische Universität Wien | A method for classifying a tumor cell sample based upon differential expression of at least two genes |
WO2005076005A3 (en) * | 2004-01-30 | 2009-02-05 | Univ Wien Med | A method for classifying a tumor cell sample based upon differential expression of at least two genes |
EP2333112A2 (en) | 2004-02-20 | 2011-06-15 | Veridex, LLC | Breast cancer prognostics |
WO2005090603A3 (en) * | 2004-03-23 | 2006-03-02 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancer |
US7700573B2 (en) | 2004-03-23 | 2010-04-20 | Oncotherapy Science, Inc. | Method for diagnosing non-small lung cancer |
US7972772B2 (en) | 2004-03-23 | 2011-07-05 | Oncotherapy Science, Inc. | KIF11 and method for diagnosing non-small cell lung cancer |
JP4938451B2 (en) * | 2004-03-23 | 2012-05-23 | オンコセラピー・サイエンス株式会社 | Methods for diagnosis of non-small cell lung cancer |
JP2007530006A (en) * | 2004-03-23 | 2007-11-01 | オンコセラピー・サイエンス株式会社 | Methods for diagnosis of non-small cell lung cancer |
WO2005090991A1 (en) * | 2004-03-24 | 2005-09-29 | Oncotherapy Science, Inc. | Adam8 as tumor marker and therapeutic target for non-small cell lung cancer |
EP1735461A4 (en) * | 2004-04-06 | 2008-10-29 | Univ California | Orphan receptor tyrosine kinase as a target in breast cancer |
JP2007532111A (en) * | 2004-04-06 | 2007-11-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Orphan receptor tyrosine kinase as a target in breast cancer |
EP1735461A1 (en) * | 2004-04-06 | 2006-12-27 | The Regents Of The University Of California | Orphan receptor tyrosine kinase as a target in breast cancer |
WO2005097204A1 (en) * | 2004-04-09 | 2005-10-20 | Takeda Pharmaceutical Company Limited | Preventives/remedies for cancer |
EP2070546A1 (en) | 2004-04-09 | 2009-06-17 | Takeda Pharmaceutical Company Limited | Preventives/remedies for cancer |
US9023605B2 (en) | 2004-04-22 | 2015-05-05 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US11401347B2 (en) | 2004-04-22 | 2022-08-02 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US8008442B2 (en) | 2004-04-22 | 2011-08-30 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US9617346B2 (en) | 2004-04-22 | 2017-04-11 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US10597463B2 (en) | 2004-04-22 | 2020-03-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
US7482129B2 (en) * | 2004-05-04 | 2009-01-27 | Institute Of Virology, Slovak Academy Of Sciences | MN/CA IX/CA9 and Renal Cancer Prognosis |
EP2258867A3 (en) * | 2004-05-11 | 2011-04-06 | Ganymed Pharmaceuticals AG | Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
US9533043B2 (en) | 2004-05-11 | 2017-01-03 | Biontech Ag | Identification of surface-associated antigens for tumor diagnosis and therapy |
AU2012200098B2 (en) * | 2004-05-11 | 2014-05-08 | Ganymed Pharmaceuticals Ag | Identification of surface-associated antigens for tumour diagnosis and therapy |
AU2014208220B2 (en) * | 2004-05-11 | 2016-08-04 | Ganymed Pharmaceuticals Ag | Identification of surface-associated antigens for tumor diagnosis and therapy |
EP2275571A3 (en) * | 2004-05-11 | 2012-11-21 | Ganymed Pharmaceuticals AG | Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
EP2267158A3 (en) * | 2004-05-11 | 2011-04-06 | Ganymed Pharmaceuticals AG | Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
US10724103B2 (en) | 2004-05-11 | 2020-07-28 | Biontech Ag | Identification of surface associated antigen FLJ31461 for tumor diagnosis and therapy |
US9255131B2 (en) | 2004-05-11 | 2016-02-09 | Ganymed Pharmaceuticals Ag | Identification of surface-associated antigens for tumor diagnosis and therapy |
EP1774043A2 (en) * | 2004-05-28 | 2007-04-18 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
EP1774043A4 (en) * | 2004-05-28 | 2009-09-02 | Dana Farber Cancer Inst Inc | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
US10538816B2 (en) | 2004-06-04 | 2020-01-21 | Biotheranostics, Inc. | Identification of tumors |
US20130023441A1 (en) * | 2004-06-04 | 2013-01-24 | Biotheranostics, Inc. | Identification of Tumors |
US9670553B2 (en) | 2004-06-04 | 2017-06-06 | Biotheranostics, Inc. | Determining tumor origin |
WO2006002433A2 (en) * | 2004-06-24 | 2006-01-05 | Veridex, Llc | Methods and reagents for the detection of melanoma |
WO2006002433A3 (en) * | 2004-06-25 | 2006-08-24 | Veridex Llc | Methods and reagents for the detection of melanoma |
WO2006027693A3 (en) * | 2004-09-09 | 2006-07-06 | Exonhit Therapeutics Sa | Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis |
WO2006027693A2 (en) * | 2004-09-09 | 2006-03-16 | Exonhit Therapeutics Sa | Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis |
EP1812794A4 (en) * | 2004-10-13 | 2008-09-10 | A & G Pharmaceutical Inc | Autocrine growth factor receptors and methods |
EP1812794A2 (en) * | 2004-10-13 | 2007-08-01 | A & G Pharmaceutical, Inc. | Autocrine growth factor receptors and methods |
US8647624B2 (en) | 2004-10-15 | 2014-02-11 | Seattle Genetics, Inc. | Treatment of immune disorders with anti-CD70 antibody |
US7641903B2 (en) | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US9051372B2 (en) | 2004-10-15 | 2015-06-09 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment of cancer and immune disorders |
US7491390B2 (en) | 2004-10-15 | 2009-02-17 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
WO2006053442A1 (en) * | 2004-11-22 | 2006-05-26 | Diagnocure Inc. | Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis |
WO2006056080A1 (en) * | 2004-11-29 | 2006-06-01 | Diagnocure Inc. | Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis |
EP1828237A1 (en) * | 2004-12-22 | 2007-09-05 | Kim, Hyun-Kee | Human cancer suppressor gene, protein encoded therein, expression vector containing the same, and cell transformed by the vector |
EP1828237A4 (en) * | 2004-12-22 | 2008-06-11 | Kim Hyun Kee | Human cancer suppressor gene, protein encoded therein, expression vector containing the same, and cell transformed by the vector |
US8535914B2 (en) * | 2005-01-21 | 2013-09-17 | Canon Kabushiki Kaisha | Probe, probe set and information acquisition method using the same |
EP1871793A4 (en) * | 2005-03-30 | 2009-04-22 | Kim Hyun Kee | Human protooncogene and protein encoded by same |
US8562987B2 (en) | 2005-04-19 | 2013-10-22 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
US9428585B2 (en) | 2005-04-19 | 2016-08-30 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
US9701752B2 (en) | 2005-04-19 | 2017-07-11 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
US8067546B2 (en) | 2005-04-19 | 2011-11-29 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
EP2177614A3 (en) * | 2005-05-02 | 2010-08-11 | Toray Industries, Inc. | Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer |
US7932032B2 (en) | 2005-05-02 | 2011-04-26 | Toray Industries, Inc. | Method for diagnosing esophageal cancer |
US8198025B2 (en) | 2005-05-02 | 2012-06-12 | Toray Industries, Inc. | Method for diagnosing esophageal cancer |
EP2518166A3 (en) * | 2005-05-20 | 2013-01-09 | Veridex, LLC | Thyroid fine needle aspiration molecular assay |
US11430544B2 (en) | 2005-06-03 | 2022-08-30 | Biotheranostics, Inc. | Identification of tumors and tissues |
US8716021B2 (en) | 2005-09-07 | 2014-05-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of replicators to prevent gene silencing |
WO2007048978A3 (en) * | 2005-10-28 | 2007-09-07 | Biomerieux Sa | Method for detecting cancer |
WO2007048978A2 (en) * | 2005-10-28 | 2007-05-03 | Biomerieux Sa | Method for detecting cancer |
WO2007074341A1 (en) * | 2005-12-28 | 2007-07-05 | Randox Laboratories Ltd | Detection of oesophageal cancer |
WO2008045133A2 (en) * | 2006-03-03 | 2008-04-17 | Veridex, Llc | Molecular assay to predict recurrence of dukes' b colon cancer |
WO2008045133A3 (en) * | 2006-03-03 | 2008-09-12 | Veridex Llc | Molecular assay to predict recurrence of dukes' b colon cancer |
WO2007128984A3 (en) * | 2006-04-06 | 2008-09-25 | Randox Lab Ltd | Breast cancer makers |
WO2007128984A2 (en) * | 2006-04-06 | 2007-11-15 | Randox Laboratories Ltd | Breast cancer makers |
EP2021034A2 (en) * | 2006-04-28 | 2009-02-11 | Inis Biotech LLC | An isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells |
EP2021034A4 (en) * | 2006-04-28 | 2010-04-21 | Inis Biotech Llc | An isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells |
US20100113569A1 (en) * | 2006-04-28 | 2010-05-06 | Inis Biotech Llc | Isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells |
WO2008024009A1 (en) * | 2006-08-15 | 2008-02-28 | Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) | Transcriptional level of a timp3 gene in the form of a diagnosis marker of a non-small cell carcinoma of lung |
EA010571B1 (en) * | 2006-08-15 | 2008-10-30 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Method for diagnosis of non-small cell carcinoma of lung and a kit therefor |
EP2052739A1 (en) * | 2006-08-16 | 2009-04-29 | Forerunner Pharma Research Co., Ltd. | Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient |
EP2052739A4 (en) * | 2006-08-16 | 2010-01-06 | Forerunner Pharma Res Co Ltd | Cancer therapeutic agent comprising ligand for neuromedin u receptor 2 (fm4) molecule as active ingredient |
US8436147B2 (en) | 2006-10-27 | 2013-05-07 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
US8889847B2 (en) | 2006-10-27 | 2014-11-18 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
US9593167B2 (en) | 2006-10-27 | 2017-03-14 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
US8410069B2 (en) | 2007-03-21 | 2013-04-02 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of Nrf2 and methods of use thereof for treatment of cancer |
WO2008114262A3 (en) * | 2007-03-21 | 2010-02-25 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer |
US7812002B2 (en) | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
WO2008151110A3 (en) * | 2007-06-01 | 2009-01-22 | Univ North Carolina | Molecular diagnosis and typing of lung cancer variants |
US10196687B2 (en) | 2007-06-01 | 2019-02-05 | University Of North Carolina At Chapel Hill | Molecular diagnosis and typing of lung cancer variants |
WO2008151110A2 (en) * | 2007-06-01 | 2008-12-11 | The University Of North Carolina At Chapel Hill | Molecular diagnosis and typing of lung cancer variants |
US8822153B2 (en) | 2007-06-01 | 2014-09-02 | The University Of North Carolina At Chapel Hill | Molecular diagnosis and typing of lung cancer variants |
WO2008154249A3 (en) * | 2007-06-08 | 2009-07-16 | Genentech Inc | Gene expression markers of tumor resistance to her2 inhibitor treatment |
WO2009021680A1 (en) * | 2007-08-14 | 2009-02-19 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
WO2009052567A1 (en) * | 2007-10-23 | 2009-04-30 | Clinical Genomics Pty. Ltd. | A method of diagnosing neoplasms - ii |
AU2008316313B2 (en) * | 2007-10-23 | 2015-04-16 | Clinical Genomics Pty. Ltd. | A method of diagnosing neoplasms - II |
CN102027128A (en) * | 2008-02-11 | 2011-04-20 | 哈达斯特医学服务与开发有限公司 | Colon cancer associated transcript 1 (CCAT-1) as a cancer marker |
WO2009101620A1 (en) * | 2008-02-11 | 2009-08-20 | Hadasit Medical Research Services & Development Limited | Colon cancer associated transcript 1 (ccat1) as a cancer marker |
US9120854B2 (en) | 2008-04-11 | 2015-09-01 | Seattle Genetics, Inc. | Detection and treatment of pancreatic, ovarian and other cancers |
US11319526B2 (en) | 2008-05-02 | 2022-05-03 | Seagen Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
US9260499B2 (en) | 2008-10-20 | 2016-02-16 | Sapporo Medical University | Tumor antigen peptide and use thereof |
US8491905B2 (en) | 2008-11-26 | 2013-07-23 | Allergan, Inc. | KLK-13 antibody inhibitor for treating dry eye |
US8211434B2 (en) | 2008-11-26 | 2012-07-03 | Allergan, Inc. | KLK-13 antibody inhibitor for treating dry eye |
US8821874B2 (en) | 2008-11-26 | 2014-09-02 | Allergan, Inc. | KLK-13 antibody inhibitor for treating dry eye |
WO2011009036A1 (en) * | 2009-07-16 | 2011-01-20 | Soymeds, Inc. | Soybean derived human thyroglobulin, methods of producing and applications thereof |
WO2011013729A1 (en) | 2009-07-30 | 2011-02-03 | オンコセラピー・サイエンス株式会社 | Fused imidazole derivative having ttk inhibitory action |
US8637642B2 (en) | 2010-09-29 | 2014-01-28 | Seattle Genetics, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
US9962454B2 (en) | 2010-09-29 | 2018-05-08 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
USRE48389E1 (en) | 2010-09-29 | 2021-01-12 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
US10894090B2 (en) | 2010-09-29 | 2021-01-19 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
US9314538B2 (en) | 2010-09-29 | 2016-04-19 | Agensys, Inc. | Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
US9078931B2 (en) | 2010-09-29 | 2015-07-14 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
US11559582B2 (en) | 2010-09-29 | 2023-01-24 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
WO2016083360A1 (en) * | 2014-11-25 | 2016-06-02 | Ait Austrian Institute Of Technology Gmbh | Diagnosis of lung cancer |
JP2021003136A (en) * | 2015-05-15 | 2021-01-14 | 国立大学法人高知大学 | Pancreatic cancer diagnostic kit |
US11180571B2 (en) | 2017-04-03 | 2021-11-23 | Hoffmann-La Roche Inc. | Antibodies binding to STEAP-1 |
US11685790B2 (en) | 2017-04-03 | 2023-06-27 | Hoffmann-La Roche Inc. | Antibodies binding to STEAP-1 |
US11820827B2 (en) | 2019-12-30 | 2023-11-21 | Seagen Inc. | Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies |
Also Published As
Publication number | Publication date |
---|---|
AU2001264559A8 (en) | 2001-12-17 |
WO2001094629A3 (en) | 2003-09-04 |
JP2004509612A (en) | 2004-04-02 |
AU2001264559A1 (en) | 2001-12-17 |
CA2411601A1 (en) | 2001-12-13 |
WO2001094629A8 (en) | 2002-05-16 |
EP1358349A2 (en) | 2003-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001094629A2 (en) | Cancer gene determination and therapeutic screening using signature gene sets | |
US20080050379A1 (en) | Cancer gene determination and therapeutic screening using signature gene sets | |
EP2444505B1 (en) | Urine markers for detection of bladder cancer | |
US20080305493A1 (en) | Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods | |
EP2691538A1 (en) | Markers associated with cyclin-dependent kinase inhibitors | |
US20020115057A1 (en) | Process for identifying anti-cancer therapeutic agents using cancer gene sets | |
JP6387001B2 (en) | Biomarkers associated with CDK inhibitors | |
US20040115625A1 (en) | Cancer gene determination and therapeutic screening using signature gene sets | |
EP1980627A1 (en) | Method of determining a chemotherapeutic regime and survival expectancy for non small cell lung cancer based on EGFR/CSF-1/CA IX expression | |
KR101200194B1 (en) | Use of SOCS6 as a hepatocellular carcinomar diagnostic marker | |
US20020165180A1 (en) | Process for identifying anti-cancer therapeutic agents using cancer gene sets | |
US20020102531A1 (en) | Cancer gene determination and therapeutic screening using signature gene sets | |
US20020102532A1 (en) | Cancer gene determination and therapeutic screening using signature gene sets | |
EP1399584A2 (en) | Cancer-linked genes as targets for chemotherapy | |
Aref-Eshghi et al. | The oncogenic roles of NTRK fusions and methods of molecular diagnosis | |
CA2328377A1 (en) | A novel method of diagnosing, monitoring, and staging prostate cancer | |
US20020150877A1 (en) | Cancer gene determination and therapeutic screening using signature gene sets | |
US20030165839A1 (en) | Cancer gene determination and therapeutic screening using signature gene sets | |
US20060134622A1 (en) | Amplified cancer target genes useful in diagnosis and thereapeutic screening | |
US20020110821A1 (en) | Cancer gene determination and therapeutic screening using signature gene sets | |
Spandidos et al. | Prognostic significance of oncogenes and tumor suppressor genes in human malignancy | |
US20020081301A1 (en) | Cancer gene determination and therapeutic screening using signature gene sets | |
AU2017254960B2 (en) | Urine markers for detection of bladder cancer | |
JP2003528630A (en) | Human genes and expression products | |
Wang et al. | Differential gene expression profiling in aggressive bladder transitional cell carcinoma compared to the adjacent microscopically normal urothelium by microdissection-SMART cDNA PCR-SSH |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 50/2001 UNDER "PUBLISHED", DELETE "SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU." |
|
CFP | Corrected version of a pamphlet front page | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001938990 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2411601 Country of ref document: CA |
|
ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2002 502169 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2001938990 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001938990 Country of ref document: EP |